

LIFEPOINT HEALTH, INC.
Form 10-Q
October 28, 2016
Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 10-Q

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF 1934

For the quarterly period ended September 30, 2016

or

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF 1934

For the transition period from to

Commission file number: 000-51251

LifePoint Health, Inc.

Edgar Filing: LIFEPOINT HEALTH, INC. - Form 10-Q

(Exact Name of Registrant as Specified in its Charter)

Delaware 20-1538254
(State or Other Jurisdiction of (I.R.S. Employer
Incorporation or Organization) Identification No.)

330 Seven Springs Way
Brentwood, Tennessee 37027
(Address Of Principal Executive Offices) (Zip Code)

(615) 920-7000
(Registrant's Telephone Number, Including Area Code)

Not Applicable

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act:

Large accelerated filer Accelerated filer Non-accelerated filer Smaller reporting company
(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes
No

As of October 21, 2016, the number of outstanding shares of the registrant’s Common Stock was 40,155,915.

Table of Contents

LifePoint Health, Inc.

TABLE OF CONTENTS

PART I - FINANCIAL INFORMATION

Item 1.	<u>Financial Statements</u>	1
Item 2.	<u>Management's Discussion and Analysis of Financial Condition and Results of Operations</u>	31
Item 3.	<u>Quantitative and Qualitative Disclosures About Market Risk</u>	60
Item 4.	<u>Controls and Procedures</u>	60

PART II - OTHER INFORMATION

Item 1.	<u>Legal Proceedings</u>	61
Item 1A.	<u>Risk Factors</u>	62
Item 2.	<u>Unregistered Sales of Equity Securities and Use of Proceeds</u>	63
Item 6.	<u>Exhibits</u>	64

Table of Contents

PART I – FINANCIAL INFORMATION

Item 1. Financial Statements.

LIFEPOINT HEALTH, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

Unaudited

(In millions, except per share amounts)

al

	Three Months Ended		Nine Months Ended	
	September 30, 2016	2015	September 30, 2016	2015
Revenues before provision for doubtful accounts	\$ 1,821.1	\$ 1,522.3	\$ 5,438.2	\$ 4,443.7
Provision for doubtful accounts	235.4	212.8	679.4	600.1
Revenues	1,585.7	1,309.5	4,758.8	3,843.6
Salaries and benefits	755.0	626.2	2,281.0	1,844.2
Supplies	262.0	205.7	793.3	596.6
Other operating expenses	384.1	313.2	1,179.3	915.5
Other income	(3.4)	(8.3)	(19.8)	(34.2)
Depreciation and amortization	86.2	70.2	257.1	207.1
Interest expense, net	36.9	28.2	112.8	84.7
Debt transaction costs	-	-	22.0	-
Impairment charges	-	2.2	1.2	13.8
	1,520.8	1,237.4	4,626.9	3,627.7
Income before income taxes	64.9	72.1	131.9	215.9
Provision for income taxes	23.7	26.3	46.7	78.3
Net income	41.2	45.8	85.2	137.6
Less: Net income attributable to noncontrolling interests and redeemable noncontrolling interests	(1.7)	(2.2)	(7.2)	(8.7)
Net income attributable to LifePoint Health, Inc.	\$ 39.5	\$ 43.6	\$ 78.0	\$ 128.9

Edgar Filing: LIFEPOINT HEALTH, INC. - Form 10-Q

Weighted average shares outstanding - basic	42.0	44.0	42.7	44.1
Effect of dilutive stock options and other stock-based awards	1.1	2.3	1.2	2.2
Weighted average shares outstanding - diluted	43.1	46.3	43.9	46.3

Earnings per share attributable to LifePoint Health, Inc. stockholders:

Basic	\$ 0.94	\$ 0.99	\$ 1.83	\$ 2.92
Diluted	\$ 0.92	\$ 0.94	\$ 1.78	\$ 2.79

See accompanying notes

Table of Contents

LIFEPOINT HEALTH, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(Dollars in millions, except per share amounts)

	September 30, 2016 (Unaudited)	December 31, 2015 (a)
ASSETS		
Current assets:		
Cash and cash equivalents	\$ 240.9	\$ 284.0
Accounts receivable, less allowances for doubtful accounts of \$874.6 and \$796.8 at September 30, 2016 and December 31, 2015, respectively	896.8	743.7
Inventories	153.8	127.7
Prepaid expenses	63.0	50.8
Other current assets	58.5	59.8
	1,413.0	1,266.0
Property and equipment:		
Land	185.9	162.8
Buildings and improvements	2,739.4	2,272.3
Equipment	1,978.8	1,767.8
Construction in progress (estimated costs to complete and equip after September 30, 2016 is \$611.3)	210.3	119.4
	5,114.4	4,322.3
Accumulated depreciation	(2,066.9)	(1,840.0)
	3,047.5	2,482.3
Intangible assets, net	66.9	70.6
Other long-term assets	80.4	510.4
Goodwill	1,721.0	1,667.5
Total assets	\$ 6,328.8	\$ 5,996.8
LIABILITIES AND EQUITY		
Current liabilities:		
Accounts payable	\$ 224.5	\$ 164.3
Accrued salaries	210.5	206.0
Income taxes payable	26.4	28.9
Other current liabilities	300.7	194.5
Current maturities of long-term debt	21.5	25.0
	783.6	618.7
Long-term debt, net	2,889.2	2,643.8

Edgar Filing: LIFEPOINT HEALTH, INC. - Form 10-Q

Deferred income taxes	44.5	94.4
Long-term portion of reserves for self-insurance claims	168.5	154.7
Other long-term liabilities	84.6	72.8
Total liabilities	3,970.4	3,584.4
Redeemable noncontrolling interests	105.7	103.6
Equity:		
LifePoint Health, Inc. stockholders' equity:		
Preferred stock, \$0.01 par value; 10,000,000 shares authorized; no shares issued	-	-
Common stock, \$0.01 par value; 90,000,000 shares authorized; 67,056,181 and 66,613,238 shares issued at September 30, 2016 and December 31, 2015, respectively	0.7	0.7
Capital in excess of par value	1,578.4	1,556.4
Accumulated other comprehensive loss	(2.7)	(2.7)
Retained earnings	1,733.0	1,655.0
Common stock in treasury, at cost, 26,121,396 and 23,480,203 shares at September 30, 2016 and December 31, 2015, respectively	(1,104.5)	(945.5)
Total LifePoint Health, Inc. stockholders' equity	2,204.9	2,263.9
Noncontrolling interests	47.8	44.9
Total equity	2,252.7	2,308.8
Total liabilities and equity	\$ 6,328.8	\$ 5,996.8

(a) Derived from audited consolidated financial statements.

See accompanying notes

Table of Contents

LIFEPOINT HEALTH, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

Unaudited

(In Millions)

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2016	2015	2016	2015
Cash flows from operating activities:				
Net income	\$ 41.2	\$ 45.8	\$ 85.2	\$ 137.6
Adjustments to reconcile net income to net cash provided by operating activities:				
Stock-based compensation	5.6	7.4	23.0	22.4
Depreciation and amortization	86.2	70.2	257.1	207.1
Amortization of physician minimum revenue guarantees	2.4	3.0	7.5	9.3
Amortization of debt issuance costs, discount and premium	1.3	1.3	4.2	3.8
Debt transaction costs	-	-	22.0	-
Impairment charges	-	2.2	1.2	13.8
Deferred income taxes	1.3	(7.7)	(47.7)	3.1
Reserve for self-insurance claims, net of payments	2.4	6.7	27.7	15.5
Increase (decrease) in cash from operating assets and liabilities, net of effects from acquisitions and divestitures:				
Accounts receivable	23.0	8.0	(105.3)	35.2
Inventories, prepaid expenses and other current assets	5.9	(0.8)	5.0	52.3
Accounts payable, accrued salaries and other current liabilities	5.5	19.7	59.1	5.4
Income taxes payable/receivable	2.6	19.2	(2.5)	38.2
Other	0.2	(0.7)	(3.8)	(1.4)
Net cash provided by operating activities	177.6	174.3	332.7	542.3
Cash flows from investing activities:				
Purchases of property and equipment	(103.4)	(59.2)	(226.3)	(153.4)
Acquisitions, net of cash acquired	(1.8)	(148.7)	(120.3)	(174.5)
Proceeds from sale of hospital	-	-	-	18.8
Other	0.4	(1.3)	(0.6)	0.5
Net cash used in investing activities	(104.8)	(209.2)	(347.2)	(308.6)

Edgar Filing: LIFEPOINT HEALTH, INC. - Form 10-Q

Cash flows from financing activities:				
Proceeds from borrowings	-	-	1,350.0	-
Payments of borrowings	(4.4)	(5.7)	(1,182.0)	(11.3)
Repurchases of common stock	(101.4)	(68.2)	(159.0)	(102.0)
Payments of debt financing costs	-	(0.2)	(30.0)	(0.3)
Proceeds from exercise of stock options	-	0.3	2.3	11.1
Other	(0.3)	(0.9)	(9.9)	(9.5)
Net cash used in financing activities	(106.1)	(74.7)	(28.6)	(112.0)
Change in cash and cash equivalents	(33.3)	(109.6)	(43.1)	121.7
Cash and cash equivalents at beginning of period	274.2	422.8	284.0	191.5
Cash and cash equivalents at end of period	\$ 240.9	\$ 313.2	\$ 240.9	\$ 313.2
Supplemental disclosure of cash flow information:				
Interest payments	\$ 4.8	\$ 4.0	\$ 76.7	\$ 55.6
Capitalized interest	\$ 1.4	\$ 0.5	\$ 3.6	\$ 1.3
Income tax payments, net	\$ 19.9	\$ 14.8	\$ 96.8	\$ 37.0

See accompanying notes

Table of Contents

LIFEPOINT HEALTH, INC.

CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY

For the Nine Months Ended September 30, 2016

Unaudited

(In Millions)

	LifePoint Health, Inc. Stockholders							
	Common	Stock	Capital in	Accumulated	Retained	Treasury	Noncontrolling	
	Shares	Amount	Excess of	Other	Earnings	Stock	Interests	Total
			Par Value	Comprehensive				
				Loss				
Balance at December 31, 2015 (a)	43.1	\$ 0.7	\$ 1,556.4	\$ (2.7)	\$ 1,655.0	\$ (945.5)	\$ 44.9	\$ 2,308.8
Net income	-	-	-	-	78.0	-	(1.5)	76.5
Exercise of stock options and tax benefits of stock-based awards	0.5	-	4.6	-	-	-	-	4.6
Stock-based compensation	-	-	23.0	-	-	-	-	23.0
Repurchases of common stock, at cost	(2.7)	-	-	-	-	(159.0)	-	(159.0)
Noncash change in noncontrolling interests as a result of acquisition and other	-	-	(5.6)	-	-	-	5.8	0.2
Cash distributions to noncontrolling interests	-	-	-	-	-	-	(1.4)	(1.4)
	40.9	\$ 0.7	\$ 1,578.4	\$ (2.7)	\$ 1,733.0	\$ (1,104.5)	\$ 47.8	\$ 2,252.7

Balance at September
30, 2016

(a) Derived from audited consolidated financial statements.

See accompanying notes

4

Table of Contents

LIFEPOINT HEALTH, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2016

Unaudited

Note 1. Organization, Basis of Presentation and Recently Issued Accounting Standards

Organization

LifePoint Health, Inc., a Delaware corporation, acting through its subsidiaries, owns and operates community hospitals, regional health systems, physician practices, outpatient centers, and post-acute facilities in 22 states throughout the United States (“U.S.”). Unless the context otherwise indicates, LifePoint Health, Inc. and its subsidiaries are referred to herein as “LifePoint” or the “Company.”

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. In the opinion of management, all adjustments, consisting of normal recurring adjustments, and disclosures considered necessary for a fair presentation have been included. Operating results for the three and nine months ended September 30, 2016 are not necessarily indicative of the results that may be expected for the year ending December 31, 2016. For further information, refer to the consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2015.

Additionally, the accompanying unaudited condensed consolidated financial statements include the accounts of the Company and all subsidiaries and entities controlled by the Company through its direct or indirect ownership of a majority interest and exclusive rights granted to the Company as the sole general partner or controlling member of such entities, including Duke LifePoint Healthcare, a joint venture between LifePoint and a wholly-controlled affiliate of Duke University Health System, Inc., and the Regional Health Network of Kentucky and Southern Indiana, a joint venture between LifePoint and Norton Healthcare, Inc. Furthermore, the Company consolidates any entities for which it receives the majority of the entity’s expected returns or is at risk for the majority of the entity’s expected losses based upon its investment or financial interest in the entity. All significant intercompany accounts and transactions within the Company have been eliminated in consolidation.

Adoption of Recently Issued Accounting Standards

ASU 2015-16, “Business Combinations: Simplifying the Accounting for Measurement-Period Adjustments”

In September 2015, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2015-16, “Business Combinations: Simplifying the Accounting for Measurement-Period Adjustments” (“ASU 2015-16”). ASU 2015-16 eliminates the requirement for an acquirer to retrospectively adjust its financial statements for changes to provisional amounts that are identified during the measurement-period following the consummation of a business combination. Instead, ASU 2015-16 requires these types of adjustments to be made during the reporting period in which they are identified and would require additional disclosure or separate presentation of the portion of the adjustment that would have been recorded in the previously reported periods as if the adjustment to the provisional amounts had been recognized as of the acquisition date. The Company adopted ASU 2015-16 during the first quarter of 2016, which had no impact on the Company’s financial position, results of operation, cash flows or financial disclosures.

Table of Contents

LIFEPOINT HEALTH, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2016

Unaudited

ASU 2015-5, “Intangibles – Goodwill and Other – Internal-Use Software”

In April 2015, the FASB issued ASU 2015-5, “Intangibles - Goodwill and Other - Internal-Use Software” (“ASU 2015-5”). ASU 2015-5 provides guidance to customers about whether a cloud computing arrangement includes a software license. If a cloud computing arrangement includes a software license, ASU 2015-5 specifies that the customer should account for the software license element of the arrangement consistent with the acquisition of other software licenses. ASU 2015-5 further specifies that the customer should account for a cloud computing arrangement as a service contract if the arrangement does not include a software license. The Company prospectively adopted the provisions of ASU 2015-5 during the first quarter of 2016, which had no material impact on the Company’s financial position, results of operation, cash flows or financial disclosures.

ASU 2015-2, “Consolidation”

In February 2015, the FASB issued ASU 2015-2 “Consolidation” (“ASU 2015-2”). ASU 2015-2 includes amendments that are intended to improve targeted areas of consolidation for legal entities including reducing the number of consolidation models from four to two and simplifying the FASB Accounting Standards Codification (“ASC”). The Company adopted ASU 2015-2 during the first quarter of 2016, which had no impact on the Company’s financial position, results of operation, cash flows or financial disclosures.

Accounting Standards Not Yet Adopted

ASU 2016-9, “Compensation – Stock Compensation: Improvements to Employee Share-Based Payment Accounting”

In March 2016, the FASB issued ASU 2016-9 “Compensation – Stock Compensation: Improvements to Employee Share-Based Payment Accounting” (“ASU 2016-9”). ASU 2016-9 changes certain aspects of accounting for share-based payment awards to employees, including the accounting for income taxes, application of estimated rates of forfeiture and statutory tax withholding requirements. ASU 2016-9 is effective for annual reporting periods beginning after December 15, 2016, including interim periods within those years. Early adoption is permitted. The Company is currently evaluating the impact that the adoption of this standard will have on its financial position, results of operations and cash flows.

ASU 2016-2, “Leases”

In February 2016, the FASB issued ASU 2016-2 “Leases” (“ASU 2016-2”). ASU 2016-2 requires the rights and obligations arising from lease contracts, including existing and new arrangements, to be recognized as assets and liabilities on the balance sheet. ASU 2016-2 is effective for annual reporting periods beginning after December 15, 2018, including interim periods within those years. Early adoption is permitted. The Company anticipates that the adoption of ASU 2016-2 will result in an increase in both total assets and total liabilities. The Company is still evaluating the impact that the adoption of this standard will have on its policies, procedures and control framework.

ASU 2014-9, “Revenue from Contracts with Customers”

In May 2014, the FASB issued ASU 2014-9, “Revenue from Contracts with Customers” (“ASU 2014-9”). ASU 2014-9 provides for a single comprehensive principles-based standard for the recognition of revenue across all industries through the application of the following five-step process:

Step 1: Identify the contract(s) with a customer.

Step 2: Identify the performance obligations in the contract.

Step 3: Determine the transaction price.

Step 4: Allocate the transaction price to the performance obligations in the contract.

Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation.

Table of Contents

LIFEPOINT HEALTH, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2016

Unaudited

Among other provisions and in addition to expanded disclosure about the nature, amount, timing and uncertainty of revenue as well as certain additional quantitative and qualitative disclosures, ASU 2014-9 changes the healthcare industry specific presentation guidance under ASU 2011-7, "Presentation and Disclosure of Patient Service Revenue, Provision for Bad Debts, and the Allowance for Doubtful Accounts for Certain Health Care Entities." The provisions of ASU 2014-9 are effective for annual periods beginning after December 15, 2017, including interim periods within those years. Early adoption is permitted starting with annual periods beginning after December 31, 2016. The Company is still evaluating the impact that the adoption of this standard will have on its revenue recognition policies, procedures, financial position, results of operations, cash flows, financial disclosures and control framework.

Note 2. Revenue Recognition and Accounts Receivable

The Company recognizes revenues in the period in which services are performed. Accounts receivable primarily consist of amounts due from third-party payors and patients. The Company's ability to collect outstanding receivables is critical to its results of operations and cash flows. Amounts the Company receives for treatment of patients covered by governmental programs such as Medicare and Medicaid and other third-party payors such as health maintenance organizations ("HMOs"), preferred provider organizations ("PPOs") and other private insurers are generally less than the Company's established billing rates. Additionally, to provide for accounts receivable that could become uncollectible in the future, the Company establishes an allowance for doubtful accounts to reduce the carrying value of such receivables to their estimated net realizable value. Accordingly, the revenues and accounts receivable reported in the accompanying unaudited condensed consolidated financial statements are recorded at the net amount expected to be received.

The Company's revenues before provision for doubtful accounts by payor and approximate percentages of revenues were as follows for the three and nine months ended September 30, 2016 and 2015 (in millions):

Three Months Ended September 30, 2016		2015		Nine Months Ended September 30, 2016		2015	
	% of		% of		% of		% of

Edgar Filing: LIFEPOINT HEALTH, INC. - Form 10-Q

	Amount	Revenues	Amount	Revenues	Amount	Revenues	Amount	Revenues
Medicare	\$ 473.4	29.9 %	\$ 390.5	29.8 %	\$ 1,423.9	29.9 %	\$ 1,145.1	29.8 %
Medicaid	230.1	14.5	223.7	17.1	698.7	14.7	634.8	16.5
HMOs, PPOs and other private insurers	863.2	54.4	674.0	51.5	2,588.4	54.4	2,020.7	52.6
Self-pay	221.0	13.9	204.9	15.7	626.8	13.2	552.0	14.3
Other	33.4	2.1	29.2	2.2	100.4	2.1	91.1	2.4
Revenues before provision for doubtful accounts	1,821.1	114.8	1,522.3	116.3	5,438.2	114.3	4,443.7	115.6
Provision for doubtful accounts	(235.4)	(14.8)	(212.8)	(16.3)	(679.4)	(14.3)	(600.1)	(15.6)
Revenues	\$ 1,585.7	100.0 %	\$ 1,309.5	100.0 %	\$ 4,758.8	100.0 %	\$ 3,843.6	100.0 %

Certain changes have been made to the Company's classification of historical sources of revenues. Specifically, the Company changed the classification of certain revenues related to its owned physician practices from HMOs, PPOs and other private insurers to the respective payor classifications, as appropriate. This change had no impact on the Company's historical results of operations.

The primary uncertainty of the Company's accounts receivable lies with uninsured patient receivables and deductibles, co-payments or other amounts due from individual patients. The Company has an established process to determine the adequacy of the allowance for doubtful accounts that relies on a number of analytical tools and benchmarks to arrive at a reasonable allowance. No single statistic or measurement determines the adequacy of the allowance for doubtful accounts. Some of the analytical tools that the Company utilizes include, but are not limited to, historical cash collection experience, revenue trends by payor classification and revenue days in accounts receivable. Accounts receivable are written off after collection efforts have been followed in accordance with the Company's policies.

Table of Contents

LIFEPOINT HEALTH, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2016

Unaudited

The following is a summary of the Company's activity in the allowance for doubtful accounts for the nine months ended September 30, 2016 (in millions):

Balance at January 1, 2016	\$ 796.8
Additions recognized as a reduction to revenues	679.4
Accounts written off, net of recoveries	(601.6)
Balance at September 30, 2016	\$ 874.6

The allowances for doubtful accounts as a percentage of gross accounts receivable, net of contractual discounts were 49.4% and 51.7% as of September 30, 2016 and December 31, 2015, respectively. The decrease in the resulting ratio of the allowance for doubtful accounts as a percentage of gross accounts receivable, net of contractual discounts, at September 30, 2016 as compared to December 31, 2015 is primarily a result of our recent acquisitions. Additionally, as of September 30, 2016 and December 31, 2015, the allowances for doubtful accounts plus certain contractual allowances and discounts related to self-pay patients as a percentage of self-pay receivables were 91.7% and 88.9%, respectively.

Note 3. General and Administrative Costs

The majority of the Company's expenses are "cost of revenue" items. Costs that could be classified as "general and administrative" by the Company would include its health support center overhead costs, which were \$49.1 million and \$57.0 million for the three months ended September 30, 2016 and 2015, respectively, and \$167.7 million and \$172.6 million for the nine months ended September 30, 2016 and 2015, respectively. Included in the Company's health support center overhead costs are depreciation and amortization expense related primarily to the Company's information systems platforms of \$9.2 million and \$7.9 million for the three months ended September 30, 2016 and 2015, and \$25.5 million and \$23.9 million for the nine months ended September 30, 2016 and 2015, respectively.

Additionally, included in the Company's health support center overhead costs are transactional expenses related to the Company's recent acquisitions, including legal and consulting fees, which were \$1.9 million and \$3.7 million for the three months ended September 30, 2016 and 2015, respectively, and \$8.1 million and \$7.0 million for the nine months ended September 30, 2016 and 2015, respectively.

Note 4. Fair Value of Financial Instruments

In accordance with ASC 825-10, "Financial Instruments" and ASC 820-10, "Fair Value Measurements and Disclosures" ("ASC 820-10"), the fair value of the Company's financial instruments are further described as follows.

Cash and Cash Equivalents, Accounts Receivable and Accounts Payable

The carrying amounts reported in the accompanying unaudited condensed consolidated balance sheets for cash and cash equivalents, accounts receivable and accounts payable approximate fair value because of the short-term maturity of these instruments.

Table of Contents

LIFEPOINT HEALTH, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2016

Unaudited

Long-Term Debt

The carrying amounts and fair values of the Company's senior secured term loan facility (the "Term Facility") under its senior secured credit agreement with, among others, Citibank, N.A. as administrative agent, and the lenders party thereto (the "Senior Credit Agreement"), the prior senior secured term loan facility (the "Prior Term Facility") and prior senior secured incremental term loans (the "Incremental Term Loans") under its prior senior secured credit agreement with, among others, Citibank, N.A. as administrative agent, and the lenders party thereto (the "Prior Credit Agreement"), 6.625% unsecured senior notes due October 1, 2020 (the "6.625% Senior Notes"), 5.5% unsecured senior notes due December 1, 2021 (the "5.5% Senior Notes"), 5.875% unsecured senior notes due December 1, 2023 (the "5.875% Senior Notes") and 5.375% unsecured senior notes due May 1, 2024 (the "5.375% Senior Notes"), excluding unamortized debt issuance costs, discount and premium, as of September 30, 2016 and December 31, 2015 were as follows (in millions):

	Carrying Amount		Fair Value	
	September 30, 2016	December 31, 2015	September 30, 2016	December 31, 2015
Senior Credit Agreement:				
Term Facility	\$ 695.6	\$ -	\$ 691.3	\$ -
Prior Credit Agreement:				
Prior Term Facility	\$ -	\$ 405.0	\$ -	\$ 404.5
Incremental Term Loans	\$ -	\$ 222.6	\$ -	\$ 222.3
6.625% Senior Notes	\$ -	\$ 400.0	\$ -	\$ 414.0
5.5% Senior Notes	\$ 1,100.0	\$ 1,100.0	\$ 1,149.5	\$ 1,105.5
5.875% Senior Notes	\$ 500.0	\$ 500.0	\$ 514.4	\$ 506.3
5.375% Senior Notes	\$ 500.0	\$ -	\$ 497.5	\$ -

The fair values of the Company's long-term debt instruments were estimated based on the average bid and ask price as determined using published rates and categorized as Level 2 within the fair value hierarchy in accordance with ASC 820-10. On June 10, 2016, the Company repaid the outstanding balances of the Prior Term Facility and the Incremental Term Loans with the proceeds from the \$700.0 million Term Facility. Additionally, on May 26, 2016, the Company issued \$500.0 million aggregate principal amount of 5.375% Senior Notes and used the proceeds, in part, to redeem all \$400.0 million aggregate principal amount of the outstanding 6.625% Senior Notes on June 13,

2016. These transactions are more fully discussed in Note 7.

Note 5. Acquisitions

Central North Carolina Market

Effective January 1, 2016, through Duke LifePoint Healthcare, the Company acquired Frye Regional Medical Center (“Frye”), a 355 bed acute care hospital located in Hickory, North Carolina and Central Carolina Hospital (“Central Carolina”), a 137 bed acute care hospital located in Sanford, North Carolina for approximately \$191.9 million in cash, including net working capital, excluding accounts receivable, plus the assumption of certain capital lease obligations of approximately \$78.0 million. The purchase price of Frye and Central Carolina, which was paid on December 31, 2015, was reflected as a deposit and was included under the caption “Other long-term assets” in the accompanying consolidated balance sheet as of December 31, 2015.

The results of operations of Frye and Central Carolina are included in the Company’s results of operations beginning on January 1, 2016. The fair values assigned to certain assets acquired and liabilities assumed in relation to the Company’s acquisitions of Frye and Central Carolina have been prepared on a preliminary basis with information currently available and are subject to change. Specifically, the Company is further assessing the valuation of certain tangible and intangible assets acquired and obligations assumed pending the final appraisals. The Company expects to finalize its analysis during the fourth quarter of 2016.

Table of Contents

LIFEPOINT HEALTH, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2016

Unaudited

St. Francis Hospital

Effective January 1, 2016, the Company acquired St. Francis Hospital (“St. Francis”), a 376 bed acute care hospital located in Columbus, Georgia for approximately \$241.5 million, net of cash acquired. The purchase price of St. Francis, which was paid on December 31, 2015, was reflected as a deposit and was included under the caption “Other long-term assets” in the accompanying consolidated balance sheet as of December 31, 2015.

The results of operations of St. Francis are included in the Company’s results of operations beginning on January 1, 2016. The fair values assigned to certain assets acquired and liabilities assumed in relation to the Company’s acquisition of St. Francis have been prepared on a preliminary basis with information currently available and are subject to change. Specifically, the Company is further assessing the valuation of certain tangible and intangible assets acquired and obligations assumed pending the final appraisals. The Company expects to finalize its analysis during the fourth quarter of 2016.

Providence Hospitals

Effective February 1, 2016, the Company acquired Providence Hospitals (“Providence”) for approximately \$132.2 million, including net working capital. Providence is comprised of Providence Hospital (Downtown), a 258 bed acute care hospital, and Providence Hospital Northeast, a 74 bed acute care hospital, each located in Columbia, South Carolina.

The results of operations of Providence are included in the Company’s results of operations beginning on February 1, 2016. The fair values assigned to certain assets acquired and liabilities assumed in relation to the Company’s acquisition of Providence have been prepared on a preliminary basis with information currently available and are subject to change. Specifically, the Company is further assessing the valuation of certain tangible and intangible assets acquired and obligations assumed pending the final appraisals. The Company expects to finalize its analysis during the fourth quarter of 2016.

Other

The Company completed certain ancillary service-line acquisitions and finalized net working capital settlements for approximately \$1.6 million during the nine months ended September 30, 2016.

Note 6. Goodwill and Intangible Assets

Goodwill

The Company accounts for its acquisitions in accordance with ASC 805-10, "Business Combinations" using the acquisition method of accounting. Goodwill represents the excess of the cost of an acquired entity over the net amounts assigned to assets acquired and liabilities assumed. In accordance with ASC 350-10, "Intangibles — Goodwill and Other" goodwill and intangible assets with indefinite lives are reviewed by the Company at least annually for impairment. The Company's business comprises a single reporting unit for impairment test purposes. For the purposes of these analyses, the Company's estimates of fair value are based on a combination of the income approach, which estimates the fair value of the Company based on its future discounted cash flows, and the market approach, which estimates the fair value of the Company based on comparable market prices. The Company performed its most recent annual impairment test as of October 1, 2015 and did not incur an impairment charge.

Table of Contents

LIFEPOINT HEALTH, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2016

Unaudited

Intangible Assets

Summary of Intangible Assets

The following table provides information regarding the Company's intangible assets, which are included in the accompanying unaudited condensed consolidated balance sheets at September 30, 2016 and December 31, 2015 (in millions):

	September 30, 2016	December 31, 2015
Amortized intangible assets:		
Contract-based physician minimum revenue guarantees		
Gross carrying amount	\$ 44.4	\$ 48.9
Accumulated amortization	(27.7)	(28.9)
Net total	16.7	20.0
Non-competition agreements and other		
Gross carrying amount	20.2	20.2
Accumulated amortization	(12.8)	(11.2)
Net total	7.4	9.0
Total amortized intangible assets		
Gross carrying amount	64.6	69.1
Accumulated amortization	(40.5)	(40.1)
Net total	24.1	29.0
Indefinite-lived intangible assets:		
Certificates of need and certificates of need exemptions	30.7	30.6
Licenses, provider numbers, accreditations and other	12.1	11.0
Net total	42.8	41.6

Total intangible assets:		
Gross carrying amount	107.4	110.7
Accumulated amortization	(40.5)	(40.1)
Net total	\$ 66.9	\$ 70.6

Contract-Based Physician Minimum Revenue Guarantees

The Company has committed to provide certain financial assistance pursuant to recruiting agreements, or “physician minimum revenue guarantees,” with various physicians practicing in the communities it serves. In consideration for a physician relocating to one of its communities and agreeing to engage in private practice for the benefit of the respective community, the Company may advance certain amounts of money to a physician to assist in establishing his or her practice.

The Company accounts for its physician minimum revenue guarantees in accordance with the provisions of ASC 460-10, “Guarantees” (“ASC 460-10”). In accordance with ASC 460-10, the Company records a contract-based intangible asset and a related guarantee liability for new physician minimum revenue guarantees. The contract-based intangible asset is amortized over the period of the physician contract, which typically ranges from four to five years and is included as an expense under the caption “Other operating expenses” in the accompanying unaudited condensed consolidated statements of operations. The Company’s liability for contract-based physician minimum revenue guarantees was \$7.6 million and \$8.1 million as of September 30, 2016 and December 31, 2015, respectively. These amounts are included in the accompanying unaudited condensed consolidated balance sheets under the caption “Other current liabilities”.

Table of Contents

LIFEPOINT HEALTH, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2016

Unaudited

Non-Competition Agreements

The Company has entered into non-competition agreements with certain physicians and other individuals which are amortized on a straight-line basis over the term of the agreements.

Certificates of Need and Certificates of Need Exemptions

The construction of new facilities, the acquisition or expansion of existing facilities and the addition of new services and certain equipment at the Company's facilities may be subject to state laws that require prior approval by state regulatory agencies. These certificate of need laws generally require that a state agency determine the public need and give approval prior to the construction or acquisition of facilities or the addition of new services. The Company has acquired facilities in certain states that have adopted certificate of need laws. The Company has determined that these intangible assets have an indefinite useful life.

Licenses, Provider Numbers, Accreditations and Other

To operate certain of its facilities, the Company must obtain certain licenses, provider numbers and accreditations from federal, state and other accrediting agencies. The Company has acquired facilities in certain jurisdictions that require licenses, provider numbers and accreditations. The Company has determined that these intangible assets have an indefinite useful life.

Note 7. Long-Term Debt

Senior Credit Agreement

Terms

On June 10, 2016, the Company replaced the Prior Credit Agreement with the Senior Credit Agreement maturing on June 10, 2021. The Senior Credit Agreement provides for the \$700.0 million Term Facility and a \$600.0 million senior secured revolving credit facility (the "Revolving Facility"). The proceeds from the Term Facility were used to repay the outstanding balances of the Prior Term Facility and Incremental Term Loans under the Company's Prior Credit Agreement and to pay related fees and expenses, and thereafter, for general corporate purposes. The Term Facility requires scheduled quarterly repayments in an amount equal to 2.5% per annum for each of the first, second and third years and 5.0% per annum for the fourth year and first three quarters of the fifth year with the balance due at maturity. Additionally, the Term Facility is subject to mandatory repayments based on excess cash flow, as well as upon the occurrence of certain other events, as specifically described in the Senior Credit Agreement. The Senior Credit Agreement is guaranteed, on a senior basis, by the Company's subsidiaries that guaranteed the Prior Credit Agreement, subject to certain exceptions. The Senior Credit Agreement is secured by collateral consisting of a perfected first priority lien on, and pledge of, all of the capital stock and intercompany notes issued by the subsidiaries of the Company and owned by the Company and each guarantor, subject to certain exceptions.

Letters of Credit and Availability

The Revolving Facility may be utilized for letters of credit and swingline loans up to a maximum of \$100.0 million and \$50.0 million, respectively. Issued letters of credit and outstanding swingline loans reduce the amounts available under the Revolving Facility. As of September 30, 2016, the Company had \$22.0 million in letters of credit outstanding that were primarily related to the self-insured retention level of its general and professional liability insurance and workers' compensation programs as security for the payment of claims. Under the terms of the Senior Credit Agreement, amounts available for borrowing under the Revolving Facility were \$578.0 million as of September 30, 2016.

Table of Contents

LIFEPOINT HEALTH, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2016

Unaudited

The Senior Credit Agreement may, subject to certain conditions and to receipt of commitments from new or existing lenders, be increased up to the sum of (i) \$800.0 million and (ii) an amount such that, after giving pro forma effect to such increase and to the use of proceeds therefrom, the Company's secured leverage ratio does not exceed 3.50:1.00; provided that no lender is obligated to participate in any such increase.

Interest Rates

Interest on the outstanding borrowings under the Senior Credit Agreement is payable at the Company's option at either an adjusted London Interbank Offer Rate ("LIBOR") or an adjusted base rate plus an applicable margin. The applicable margin under the Senior Credit Agreement ranges from 1.50% to 2.00% for LIBOR loans and from 0.50% to 1.00% for adjusted base rate loans based on the Company's total leverage ratio, calculated in accordance with the Senior Credit Agreement. As of September 30, 2016, the applicable annual interest rate under the Term Facility was 2.27%, which was based on the 30-day adjusted LIBOR of 0.52% plus the applicable margin.

Covenants

The Senior Credit Agreement requires the Company to satisfy a maximum total leverage ratio not to exceed 5.00:1.00 through June 30, 2018 with a step-down to 4.50:1.00 through the remaining term and as calculated on a trailing four quarter basis. The Company was in compliance with this covenant as of September 30, 2016.

In addition, the Senior Credit Agreement contains certain customary affirmative and negative covenants, which place limitations on the ability of the Company and its subsidiaries to, among other things, incur debt, create other liens on its assets, make investments, sell assets, pay dividends or distributions to stockholders, undertake transactions with affiliates and enter into merger transactions or consolidate with other companies. The Senior Credit Agreement also contains various customary representations and warranties, financial and collateral reporting requirements and other affirmative covenants.

Issuance of 5.375% Senior Notes and Redemption of 6.625% Senior Notes

On May 26, 2016, the Company issued in a private placement \$500.0 million aggregate principal amount of 5.375% Senior Notes due May 1, 2024. The proceeds from this issuance were used to redeem all \$400.0 million aggregate principal amount of the outstanding 6.625% Senior Notes at a redemption price of 103.313% of principal amount plus accrued and unpaid interest to the redemption date of June 13, 2016. The remaining proceeds were used

for general corporate purposes. The 5.375% Senior Notes bear interest at the rate of 5.375% per year, payable semi-annually on May 1 and November 1. The 5.375% Senior Notes are jointly and severally guaranteed on an unsecured senior basis by certain of the Company's existing and future domestic subsidiaries.

The Company may redeem up to 35% of the aggregate principal amount of the 5.375% Senior Notes, at any time before May 1, 2019, with the net cash proceeds of certain equity offerings at a redemption price equal to 105.375% of the principal amount to be redeemed, plus accrued and unpaid interest, provided that at least 65% of the aggregate principal amount of the 5.375% Senior Notes remain outstanding immediately after the occurrence of such redemption and such redemption occurs within 180 days of the date of the closing of any such qualified equity offering.

The Company may redeem the 5.375% Senior Notes, in whole or in part, at any time prior to May 1, 2019 at a price equal to 100% of the principal amount of the notes redeemed plus an applicable make-whole premium, plus accrued and unpaid interest, if any, to the date of redemption. The Company may redeem the 5.375% Senior Notes, in whole or in part, at any time on or after May 1, 2019 at the redemption prices (expressed as percentages of principal amount) listed below, plus accrued and unpaid interest, if any, to the date of redemption:

May 1, 2019 to April 30, 2020	104.031 %
May 1, 2020 to April 30, 2021	102.688 %
May 1, 2021 to April 30, 2022	101.344 %
May 1, 2022 and thereafter	100.000 %

Table of Contents

LIFEPOINT HEALTH, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2016

Unaudited

If the Company experiences a change in control under certain circumstances, it must offer to purchase the notes at a purchase price equal to 101% of the principal amount, plus accrued and unpaid interest to the date of purchase.

The 5.375% Senior Notes contain customary restrictive covenants, which among other things, limit the ability of the Company and its subsidiaries to incur or guarantee additional indebtedness; pay dividends on, or redeem or repurchase, its capital stock; make investments; incur obligations that restrict the Company's subsidiaries from making dividend or other payment to the Company; sell or encumber its assets; engage in transactions with affiliates; enter into sale/leaseback transactions; and merge, consolidate, or transfer all or substantially all of its assets.

In connection with the issuance of the 5.375% Senior Notes, the Company agreed to use commercially reasonable efforts to register with the Securities and Exchange Commission exchange notes having substantially identical terms as the 5.375% Senior Notes and complete an exchange offer no later than 395 calendar days after the issuance date of the 5.375% Senior Notes. Under certain circumstances, the Company may be required to file a shelf registration statement with respect to the 5.375% Senior Notes. If the Company fails to meet these obligations, it has agreed to pay additional interest to the holders of the affected 5.375% Senior Notes under certain circumstances.

Debt Transaction Costs

In connection with the various debt transactions discussed above, the Company capitalized \$16.0 million of new debt issuance costs and recognized debt transaction costs of approximately \$22.0 million, \$13.7 million net of income taxes, or \$0.31 loss per diluted share, during the second quarter of 2016. The debt transaction costs include the write-offs of previously capitalized issuance costs and new non-capital costs related to the Company's various debt transactions entered into during the second quarter of 2016.

Note 8. Common Stock in Treasury

The Company's Board of Directors has authorized the repurchase of outstanding shares of its common stock either in the open market or through privately negotiated transactions, subject to market conditions, regulatory constraints and other customary factors in accordance with a repurchase plan adopted in 2014, as subsequently amended and extended in October 2015 (the "2014 Repurchase Plan"), a repurchase plan adopted on June 3, 2015 (the "2015 Repurchase Plan"), and a repurchase plan adopted on September 14, 2016 (the "2016 Repurchase Plan"). The 2014 Repurchase Plan and 2015 Repurchase Plan each provided for the repurchase of up to \$150.0 million in shares of the Company's common stock, and the Company has repurchased all shares authorized for repurchase under these plans. The 2016

Repurchase Plan provides for the repurchase of up to \$200.0 million in shares of the Company's common stock through March 14, 2018. As of September 30, 2016, the Company had remaining authority to repurchase \$174.0 million in shares in accordance with the 2016 Repurchase Plan. The Company is not obligated to repurchase any specific number of shares under the 2016 Repurchase Plan. The Company has designated the shares repurchased in accordance with its repurchase plans as treasury stock.

The Company repurchased approximately 2.5 million and 1.2 million shares for an aggregate purchase price, including commissions, of \$151.0 million and \$92.5 million at an average purchase price of \$60.13 and \$75.84 per share during the nine months ended September 30, 2016 and 2015, respectively.

Additionally, the Company redeems shares from employees for minimum statutory tax withholding purposes upon vesting of certain stock awards granted pursuant to the Company's various stockholder approved stock-based compensation plans. The Company redeemed approximately 0.2 million shares vested under these plans during each of the nine months ended September 30, 2016 and 2015 for aggregate purchase prices of approximately \$8.0 million and \$9.5 million, respectively. The Company has designated these shares as treasury stock.

Table of Contents

LIFEPOINT HEALTH, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2016

Unaudited

Note 9. Stock-Based Compensation

Overview

The Company issues stock-based awards, including stock options and other stock-based awards (nonvested stock, restricted stock, restricted stock units and performance shares) to certain officers, employees and non-employee directors in accordance with the Company's stockholder-approved 2013 Long-Term Incentive Plan (the "LTIP"). The Company accounts for its stock-based awards in accordance with the provisions of ASC 718-10, "Compensation – Stock Compensation" ("ASC 718-10"), and accordingly recognizes compensation expense over each of the stock-based award's requisite service period based on the estimated grant date fair value.

Notwithstanding the specific grant vesting requirements, award agreements under the LTIP may provide for accelerated vesting in certain circumstances. Generally, award agreements provide for full vesting upon the death or disability of the participant. Some award agreements also provide for partial or full vesting upon involuntary termination of employment, provided that if the award is performance-based then the accelerated vesting would occur only if the performance goals are attained.

Stock Options

The Company granted options to purchase 939,417 and 823,750 shares of the Company's common stock to certain officers and employees in accordance with the LTIP during the nine months ended September 30, 2016 and 2015, respectively. Options to purchase shares granted to the Company's officers and employees in accordance with the LTIP were granted with an exercise price equal to the fair market value of the Company's common stock on the day of grant, determined based on the closing price on the trading date immediately prior to the grant date. The options granted during the nine months ended September 30, 2016 and 2015 become ratably exercisable beginning one year from the date of grant to three years after the date of grant and expire ten years from the date of grant.

The Company estimated the fair value of stock options granted using a binomial lattice option valuation model and a single option award approach. The Company uses a binomial lattice option valuation model because it considers characteristics of fair value option pricing, such as an option's contractual term and the probability of exercise before the end of the contractual term. In addition, the complications surrounding the expected term of an option are

material, as indicated in ASC 718-10. Given the Company's relatively large pool of unexercised options, the Company believes a binomial lattice option valuation model that specifically addresses this fact and models a full term of exercises is the most appropriate and reliable means of valuing its stock options. The Company is amortizing the fair value on a straight-line basis over the requisite service period of the awards, which is the vesting period of three years. The stock options vest 33.3% on each grant anniversary date over three years of continued employment.

The following table shows the weighted average assumptions the Company used to develop the fair value estimates under its lattice option valuation models and the resulting estimates of weighted-average fair value per share of stock options granted during the nine months ended September 30, 2016 and 2015:

	Nine Months Ended	
	September 30,	
	2016	2015
Expected volatility	32.2 %	29.0 %
Risk-free interest rate	1.76 %	2.20 %
Expected dividends	-	-
Average expected term (years)	5.9	5.3
Fair value per share of stock options granted	\$ 19.58	\$ 18.66

Table of Contents

LIFEPOINT HEALTH, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2016

Unaudited

The total intrinsic value of stock options exercised during the nine months ended September 30, 2016 and 2015 was \$1.2 million and \$8.4 million, respectively. The Company received \$2.3 million and \$11.1 million in cash from stock option exercises for the nine months ended September 30, 2016 and 2015, respectively. The actual tax benefit realized for the tax deductions from stock option exercises was nominal for the nine months ended September 30, 2016 and \$2.0 million for the nine months ended September 30, 2015.

As of September 30, 2016, there was \$18.5 million of total estimated unrecognized compensation cost related to stock option compensation arrangements. Total estimated unrecognized compensation cost will be adjusted for future changes in estimated forfeitures. The Company expects to recognize that cost over a weighted average period of 1.4 years.

Other Stock-Based Awards

The Company granted 159,868 and 144,919 restricted stock units to certain officers, employees and non-employee directors in accordance with the LTIP during the nine months ended September 30, 2016 and 2015, respectively. Vesting and payment of these restricted stock units are generally subject to continuing service of the employee or non-employee director over the ratable vesting periods beginning one year from the date of grant to three years after the date of grant or cliff-vesting periods from the grant date of six months and one day. The fair values of these restricted stock units were determined based on the closing price of the Company's common stock on the trading date immediately prior to the grant date.

Additionally, during the nine months ended September 30, 2016 and 2015, the Company granted 159,248 targeted performance-based restricted stock units subject to the achievement of a combination of performance and market conditions and 145,000 targeted performance-based restricted stock units subject to the achievement of a market condition, respectively. In addition to the achievement of the performance and/or market conditions, these performance-based restricted stock units are generally subject to the continuing service of the employee over the cliff-vesting period from the grant date of three years.

The performance condition for the targeted performance-based restricted stock units granted during the nine months ended September 30, 2016 are based on the Company's actual earnings before interest, taxes, depreciation and amortization ("EBITDA") financial performance for hospital acquisitions completed in 2014 and 2015 as compared to the pro forma EBITDA target for this same group of hospitals. The market condition for the targeted performance-based restricted stock units granted during each of the nine months ended September 30, 2016 and 2015 are based on the Company's three-year annualized total shareholder return relative to a peer group, Standard and Poor's Global Industry Classification Standard's Sub-Industry: Health Care Facilities with over \$500.0 million in revenues or

its equivalent. For these restricted stock units, the number of shares payable at the end of the three-year performance period ranges from 0% to 200% of the targeted units based on the Company's actual performance and/or market conditions results as compared to the targets.

The fair value of these restricted stock units was determined based on a combination, where applicable, of the closing price of the Company's common stock on the trading date immediately prior to the grant date for units subject to performance conditions, or at its Monte-Carlo simulation value for units subject to market conditions. The Company recognizes compensation expense for the portion of the targeted performance-based restricted stock units subject to market conditions even if the condition is never satisfied. However, if the performance conditions are not met for the portion of the targeted performance-based restricted stock units subject to such performance conditions, no compensation expense will be recognized, and any previously recognized compensation expense will be reversed.

As of September 30, 2016, there was \$23.3 million of total estimated unrecognized compensation cost related to other stock-based awards. Total estimated unrecognized compensation cost will be adjusted for future changes in estimated forfeitures. The Company expects to recognize that cost over a weighted average period of 1.6 years.

Table of Contents

LIFEPOINT HEALTH, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2016

Unaudited

The following table summarizes the Company's total stock-based compensation expense as well as the total recognized tax benefits related thereto for the three and nine months ended September 30, 2016 and 2015 (in millions):

	Three Months Ended September 30, 2016		Nine Months Ended September 30, 2015	
Equity awards:				
Other stock-based awards	\$ 3.0	\$ 4.9	\$ 13.3	\$ 14.4
Stock options	2.6	2.5	9.7	8.0
	5.6	7.4	23.0	22.4
Liability awards:				
Other stock-based awards	(3.6)	(0.5)	(7.1)	3.2
Total stock-based compensation expense	\$ 2.0	\$ 6.9	\$ 15.9	\$ 25.6
Tax benefit on stock-based compensation expense	\$ 0.8	\$ 2.8	\$ 6.3	\$ 10.2

The Company did not capitalize any stock-based compensation cost during the three or nine months ended September 30, 2016 or 2015. As of September 30, 2016, there was \$41.8 million of total estimated unrecognized compensation cost related to all of the Company's stock-based compensation arrangements. Total estimated unrecognized compensation cost may be adjusted for future changes in estimated forfeitures. The Company expects to recognize that cost over a weighted-average period of 1.5 years.

Note 10. Commitments and Contingencies

Legal Proceedings and General Liability Claims

Healthcare facilities are, from time to time, subject to claims and suits arising in the ordinary course of business, including claims for damages for personal injuries, medical malpractice, breach of contracts, wrongful restriction of or interference with physicians' staff privileges and employment related claims. In certain of these actions, plaintiffs

request payment for damages, including punitive damages that may not be covered by insurance.

In addition, healthcare facilities are subject to the regulation and oversight of various state and federal governmental agencies. Further, under the federal False Claims Act, private parties have the right to bring qui tam, or “whistleblower,” suits against healthcare facilities that submit false claims for payments to, or improperly retain overpayments from, governmental payors. Some states have adopted similar state whistleblower and false claims provisions. These qui tam or “whistleblower” actions initiated under the civil False Claims Act may be pending but placed under seal by the court to comply with the False Claims Act’s requirements for filing such suits. As a result, they could be proceeding without the Company’s knowledge. In addition, on June 30, 2016, in accordance with the requirements of the Federal Civil Penalties Inflation Adjustment Act Improvements Act of 2015, the Department of Justice (“DOJ”) published an interim final rule that, effective as of August 1, 2016, increases the civil monetary penalties that may be imposed for violations of the False Claims Act from a minimum of \$5,500 and a maximum of \$11,000 to a minimum of \$10,781 and a maximum of \$21,563 for each false and fraudulent claim. The interim final rule also establishes a mechanism for increasing the amounts of those civil monetary penalties for inflation on an annual basis beginning in 2017 and continuing each year thereafter. These civil monetary penalties are in addition to violators’ liability for three times the amount of damages which the government sustains as a result of the false or fraudulent claim.

Table of Contents

LIFEPOINT HEALTH, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2016

Unaudited

Although the healthcare industry has seen numerous ongoing investigations related to compliance and billing practices, hospitals, in particular, continue to be a primary enforcement target for the Office of Inspector General (“OIG”), the DOJ and other governmental fraud and abuse programs. Certain of the Company’s individual facilities have received, and from time to time, other facilities may receive, inquiries or subpoenas from fiscal intermediaries, and federal and state agencies. Any proceedings against the Company may involve potentially substantial amounts as well as the possibility of civil, criminal, or administrative fines, penalties, or other sanctions, which could be material. Settlements of suits involving Medicare and Medicaid issues routinely require both monetary payments as well as corporate integrity agreements. Depending on whether the underlying conduct in these or future inquiries or investigations could be considered systemic, their resolution could have a material adverse effect on the Company’s financial position, results of operations and liquidity.

The Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act of 2010 imposed an affirmative obligation on healthcare providers to report and refund any overpayments received. “Overpayments” in this context include any amount received from a government program by a provider to which it is not entitled, regardless of the cause. Such overpayments are deemed to be fraudulent and become violations of the False Claims Act if not reported and refunded within the later of 60 days of identification or the date any corresponding cost report is due (if applicable). Hospitals can meet the obligation to report and refund in three ways: (1) refunding overpayments directly to the program; (2) self-disclosing the overpayment to the OIG via its voluntary self-disclosure protocol (with respect to False Claims Act and other violations not related to the federal physician self-referral law (Stark law)); and (3) self-disclosing to the Centers for Medicare and Medicaid Services (“CMS”) via the self-referral disclosure protocol (with respect to overpayments caused by potential violations of the Stark law only) for which CMS has the authority to reduce the amounts otherwise owed.

The Company does not control and cannot predict with certainty the progress or final outcome of discussions with government agencies, investigations and legal proceedings against the Company. Therefore, the final amounts paid to resolve such matters, claims and obligations could be material and could materially differ from amounts currently recorded, if any. Any such changes in the Company’s estimates or any adverse judgments could materially adversely impact the Company’s future results of operations and cash flows.

In connection with the Company's acquisitions of Marquette General Hospital ("Marquette General") and Conemaugh Health System ("Conemaugh"), the two sellers self-disclosed various potentially non-compliant physician arrangements under the CMS voluntary self-disclosure protocol. These self-disclosures are pending with CMS. With respect to Marquette General, to the extent that the seller's satisfaction of its retained liabilities, including those under its CMS voluntary self-disclosure, causes its net proceeds from the acquisition to be less than \$15.0 million, the Company has agreed to pay additional purchase consideration to the seller. With respect to Conemaugh, to the extent that the potential settlement exceeds the seller's indemnification threshold in accordance with the asset purchase agreement, the Company will likely be responsible for funding any deficit. The Company's management believes it has made reasonable estimates of its potential exposure for these two matters and at September 30, 2016 has recorded a reserve for Marquette General of \$18.0 million.

On September 16, 2013, the Company and two of its affiliated hospitals, Vaughan Regional Medical Center, located in Selma, Alabama, and Raleigh General Hospital, located in Raleigh, West Virginia, made a voluntary self-disclosure to the Civil Division of the Department of Justice. The voluntary self-disclosure related to concerns regarding the clinical appropriateness of certain interventional cardiology procedures conducted by one physician in each of these hospitals' cardiac catheterization laboratories. On September 24, 2013, the U.S. Attorney's Office in the Southern District of West Virginia served a subpoena on Raleigh General Hospital. Raleigh General Hospital produced responsive documents to the subpoena, including patient files. The government investigations are ongoing and the Company continues to cooperate with the government in addressing these matters. Following reviews by independent interventional cardiologists, the Company notified patients of these two physicians who may have received an unnecessary procedure of such fact.

Table of Contents

LIFEPOINT HEALTH, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2016

Unaudited

The Company and/or Vaughan Regional Medical Center and several of the Company's subsidiaries, as well as Dr. Seydi V. Aksut and certain parties unaffiliated with the Company, are named defendants in 26 individual lawsuits filed since December 2014, and two putative class action lawsuits, all filed in the Circuit Court of Dallas County, Alabama. These lawsuits allege that patients at Vaughan Regional Medical Center underwent improper interventional cardiology procedures. One of the putative class action lawsuits, filed on November 21, 2014, seeks certification of a class consisting of all Alabama citizens who underwent an invasive cardiology procedure at any Company-owned Alabama hospital and who received notice regarding the medical necessity of that procedure. The other putative class action lawsuit, filed on February 6, 2015 also in the Circuit Court for Dallas County, Alabama, seeks certification of a class of individuals that underwent an interventional cardiology procedure that was not medically necessary and performed by Dr. Aksut. This action asserts, among other claims, claims under the Racketeer Influenced and Corrupt Organizations Act ("RICO"), which, if successful, would result in the awarding of treble damages for any injury resulting from the RICO violation and attorneys' fees. In March 2015, the Company removed this action to the U.S. District Court in Mobile, Alabama and filed a motion to dismiss and for summary judgment, as well as a stay of discovery pending resolution of these motions. On April 17, 2015 the court entered an order granting the requested stay of discovery. On November 17, 2015, the United States Magistrate Judge for the Southern District of Alabama filed a Report and Recommendation that the RICO claim be dismissed with prejudice, and that the court not exercise jurisdiction over the remaining state law claims, resulting in those claims being dismissed without prejudice. By Order dated March 28, 2016, the United States District Court Judge adopted in full the Report and Recommendation of the Magistrate, dismissing with prejudice the RICO claim and refusing to exercise jurisdiction over the remaining state law claims. In a filing made April 7, 2016 the plaintiffs appealed the District Court's Order to the United States Court of Appeals for the Eleventh Circuit.

Additionally, the Company, and two of its subsidiaries, including Raleigh General Hospital, as well as Dr. Kenneth Glaser, have been named in 82 individual lawsuits filed in the circuit court of Raleigh County, West Virginia. These lawsuits allege that patients at Raleigh General Hospital underwent unnecessary interventional cardiology procedures. Through September 30, 2016, one additional patient has notified Raleigh General Hospital that he intends to file a lawsuit against the hospital.

The lawsuits identified above variously seek compensatory and punitive damages, costs, attorneys' fees and other available damages. Additional claims, including claims involving patients to whom the Company did not send notice, have been threatened and may be asserted against the Company or the hospital. Any present or future claims that are ultimately successful could result in the Company and/or the hospitals being found liable and the government investigations may also result in damages, fines and penalties. Such liability, damages and penalties could be material.

The Company accrues an estimate for a contingent liability when losses are both probable and reasonably estimable. The Company reviews its accruals each quarter and adjusts them to reflect the impact of developments, advice of legal counsel and other information pertaining to a particular matter. During the nine months ended September 30, 2016, the Company recorded an accrual for loss contingencies for cardiology-related lawsuits, which resulted in a net expense of \$24.7 million, \$15.5 million net of income taxes, or \$0.35 loss per diluted share.

Physician Commitments

The Company has committed to provide certain financial assistance pursuant to recruiting agreements with various physicians practicing in the communities it serves. In consideration for a physician's relocating to one of its communities and agreeing to engage in private practice for the benefit of the respective community, the Company may advance certain amounts of money to a physician, normally over a period of one year, to assist in establishing the physician's practice. The Company has committed to advance a maximum amount of approximately \$20.0 million at September 30, 2016. The actual amount of such commitments to be subsequently advanced to physicians is estimated at \$7.6 million and often depends upon the financial results of a physician's private practice during the guarantee period. Generally, amounts advanced under the recruiting agreements may be forgiven pro rata over a period of 36 to 48 months contingent upon the physician continuing to practice in the respective community. Pursuant to the Company's standard physician recruiting agreement, any breach or non-fulfillment by a physician under the physician recruiting agreement gives the Company the right to recover any payments made to the physician under the agreement. Additionally, the Company is subject to annual commitments for certain physician recruiting activities, including the continuation of existing or initiation of new activities with several of its facilities.

Table of Contents

LIFEPOINT HEALTH, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2016

Unaudited

Capital Expenditure Commitments

The Company is reconfiguring some of its facilities to more effectively accommodate patient services and to provide for a greater variety of services, as well as implementing various information system initiatives in its efforts to comply with the Health Information Technology for Economic and Clinical Health Act. The Company has incurred approximately \$210.3 million in costs related to uncompleted projects as of September 30, 2016, which is included under the caption "Construction in progress" in the accompanying unaudited condensed consolidated balance sheet. At September 30, 2016, these uncompleted projects had an estimated cost to complete and equip of approximately \$611.3 million. Additionally, the Company is subject to annual capital expenditure commitments in connection with several of its facilities. As part of the Company's current acquisition strategy, management expects capital expenditure commitments to be a significant component of future purchase transactions. At September 30, 2016, the Company estimated its total remaining capital expenditure commitments, including commitments for routine projects, to be approximately \$1,612.9 million. In general, these capital expenditure commitments range in term from eight to ten years following the effective date of the acquisition.

Acquisitions

The Company has historically acquired businesses with prior operating histories. Acquired businesses may have unknown or contingent liabilities, including liabilities for failure to comply with healthcare laws and regulations, medical and general professional liabilities, workers compensation liabilities, previous tax liabilities and unacceptable business practices. Although the Company institutes policies designed to conform practices to its standards following completion of acquisitions, there can be no assurance that the Company will not become liable for past activities that may later be asserted to be improper by private plaintiffs or government agencies. Although the Company generally seeks to obtain indemnification from prospective sellers covering such matters, there can be no assurance that any such matter will be covered by indemnification, or if covered, that such indemnification will be adequate to cover potential losses and fines.

Marquette Replacement Facility

In December 2015, the Company acquired a parcel of land in Marquette, Michigan, and in May 2016, began constructing a replacement hospital for the existing Marquette General hospital. The Company anticipates that it will continue to operate the existing hospital campus until such point that the replacement hospital is ready for its intended use. Management currently expects that the construction of the replacement hospital will take approximately two to three years.

In accordance with ASC 360-10, the Company performed an evaluation of the recoverability of the carrying values of certain of the assets of Marquette General which management anticipates disposing. Because the estimated future undiscounted cash flows of Marquette General exceed the carrying values of the assets being considered for disposal, the Company has determined that these long-lived assets are not impaired. However, the Company has begun accelerating its depreciation expense for the portion of the existing hospital management anticipates disposing of in the future in order to reduce its carrying value down to the estimated fair value at the end of the projected construction period of the replacement hospital. Accordingly, the Company incurred approximately \$1.5 million and \$4.7 million, \$0.9 million and \$2.9 million net of income taxes, or \$0.2 and \$0.07 loss per diluted share, of additional depreciation expense during the three and nine months ended September 30, 2016, respectively. The Company currently estimates this acceleration will result in approximately \$6.0 million of additional depreciation expense per year during the construction of the replacement hospital. This estimate is subject to change as a result of possible modifications to the Company's plans for the existing hospital, including, but not limited to, the finalization of the plans for the replacement hospital, changes in the estimated construction period for the replacement hospital, on-going discussions and negotiations with interested parties for the existing hospital, regulatory approvals and changing market conditions.

Table of Contents

LIFEPOINT HEALTH, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2016

Unaudited

Note 11. Guarantor and Non-Guarantor Supplementary Information

The 5.5% Senior Notes, 5.875% Senior Notes and 5.375% Senior Notes are jointly and severally guaranteed on an unsecured senior basis by substantially all of the Company's existing subsidiaries that guarantee the Company's Senior Credit Agreement. The guarantors are 100% owned by the Company. Additionally, the guarantees are full and unconditional and are subject to customary release provisions as set forth in the agreements for the 5.5% Senior Notes, 5.875% Senior Notes and 5.375% Senior Notes.

The condensed consolidating financial information for the parent issuer, 100% owned guarantor subsidiaries, non-guarantor subsidiaries, certain eliminations and the Company is presented below for the three and nine months ended September 30, 2016 and 2015 and as of September 30, 2016 and December 31, 2015.

LIFEPOINT HEALTH, INC.

Condensed Consolidating Statements of Operations
For the Three Months Ended September 30, 2016

(In millions)

	Parent Issuer	Guarantors	Non- Guarantors	Eliminations	Consolidated
Revenues before provision for doubtful accounts	\$ -	\$ 1,020.4	\$ 800.7	\$ -	\$ 1,821.1
Provision for doubtful accounts	-	125.0	110.4	-	235.4
Revenues	-	895.4	690.3	-	1,585.7
Salaries and benefits	2.0	420.9	332.1	-	755.0
Supplies	-	139.8	122.2	-	262.0
Other operating expenses, net	(0.9)	218.4	166.6	-	384.1

Edgar Filing: LIFEPOINT HEALTH, INC. - Form 10-Q

Other income	-	(1.3)	(2.1)	-	(3.4)
Equity in earnings of affiliates	(65.1)	-	-	65.1	-
Depreciation and amortization	-	54.6	31.6	-	86.2
Interest expense, net	31.3	1.3	4.3	-	36.9
Management (income) fees	-	(19.7)	19.7	-	-
	(32.7)	814.0	674.4	65.1	1,520.8
Income before income taxes	32.7	81.4	15.9	(65.1)	64.9
(Benefit) provision for income taxes	(6.8)	30.5	-	-	23.7
Net income	39.5	50.9	15.9	(65.1)	41.2
Less: Net income attributable to noncontrolling interests and redeemable noncontrolling interests	-	(0.2)	(1.5)	-	(1.7)
Net income attributable to LifePoint Health, Inc.	\$ 39.5	\$ 50.7	\$ 14.4	\$ (65.1)	\$ 39.5

Table of Contents

LIFEPOINT HEALTH, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2016

Unaudited

LIFEPOINT HEALTH, INC.

Condensed Consolidating Statements of Operations

For the Three Months Ended September 30, 2015

(In millions)

	Parent Issuer	Guarantors	Non- Guarantors	Eliminations	Consolidated
Revenues before provision for doubtful accounts	\$ -	\$ 860.9	\$ 661.4	\$ -	\$ 1,522.3
Provision for doubtful accounts	-	125.2	87.6	-	212.8
Revenues	-	735.7	573.8	-	1,309.5
Salaries and benefits	6.9	335.1	284.2	-	626.2
Supplies	-	106.9	98.8	-	205.7
Other operating expenses, net	(0.5)	175.2	138.5	-	313.2
Other income	-	(4.8)	(3.5)	-	(8.3)
Equity in earnings of affiliates	(55.3)	-	-	55.3	-
Depreciation and amortization	-	44.1	26.1	-	70.2
Interest expense, net	8.6	17.2	2.4	-	28.2
Impairment charge	-	2.2	-	-	2.2
Management (income) fees	-	(17.6)	17.6	-	-
	(40.3)	658.3	564.1	55.3	1,237.4
Income before income taxes	40.3	77.4	9.7	(55.3)	72.1
(Benefit) provision for income taxes	(3.3)	29.6	-	-	26.3
Net income	43.6	47.8	9.7	(55.3)	45.8
Less: Net income attributable to noncontrolling interests and redeemable noncontrolling interests	-	(0.2)	(2.0)	-	(2.2)
Net income attributable to LifePoint					

Health, Inc.	\$ 43.6	\$ 47.6	\$ 7.7	\$ (55.3)	\$ 43.6
--------------	---------	---------	--------	-----------	---------

Table of Contents

LIFEPOINT HEALTH, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2016

Unaudited

LIFEPOINT HEALTH, INC.

Condensed Consolidating Statements of Operations

For the Nine Months Ended September 30, 2016

(In millions)

	Parent Issuer	Guarantors	Non- Guarantors	Eliminations	Consolidated
Revenues before provision for doubtful accounts	\$ -	\$ 3,047.9	\$ 2,390.3	\$ -	\$ 5,438.2
Provision for doubtful accounts	-	386.0	293.4	-	679.4
Revenues	-	2,661.9	2,096.9	-	4,758.8
Salaries and benefits	15.9	1,253.1	1,012.0	-	2,281.0
Supplies	-	423.0	370.3	-	793.3
Other operating expenses, net	(0.5)	691.0	488.8	-	1,179.3
Other income	-	(10.8)	(9.0)	-	(19.8)
Equity in earnings of affiliates	(184.3)	-	-	184.3	-
Depreciation and amortization	-	160.7	96.4	-	257.1
Interest expense, net	96.3	3.7	12.8	-	112.8
Debt transaction costs	22.0	-	-	-	22.0
Impairment charge	-	1.2	-	-	1.2
Management (income) fees	-	(58.7)	58.7	-	-
	(50.6)	2,463.2	2,030.0	184.3	4,626.9
Income before income taxes	50.6	198.7	66.9	(184.3)	131.9
(Benefit) provision for income taxes	(27.4)	74.1	-	-	46.7
Net income	78.0	124.6	66.9	(184.3)	85.2
Less: Net income attributable to noncontrolling interests and redeemable noncontrolling interests	-	(0.7)	(6.5)	-	(7.2)

Net income attributable to LifePoint Health, Inc.	\$ 78.0	\$ 123.9	\$ 60.4	\$ (184.3)	\$ 78.0
---	---------	----------	---------	------------	---------

Table of Contents

LIFEPOINT HEALTH, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2016

Unaudited

LIFEPOINT HEALTH, INC.

Condensed Consolidating Statements of Operations

For the Nine Months Ended September 30, 2015

(In millions)

	Parent Issuer	Guarantors	Non- Guarantors	Eliminations	Consolidated
Revenues before provision for doubtful accounts	\$ -	\$ 2,552.2	\$ 1,891.5	\$ -	\$ 4,443.7
Provision for doubtful accounts	-	372.0	228.1	-	600.1
Revenues	-	2,180.2	1,663.4	-	3,843.6
Salaries and benefits	25.6	998.5	820.1	-	1,844.2
Supplies	-	316.3	280.3	-	596.6
Other operating expenses, net	(0.7)	544.0	372.2	-	915.5
Other income	-	(22.6)	(11.6)	-	(34.2)
Equity in earnings of affiliates	(186.4)	-	-	186.4	-
Depreciation and amortization	-	134.0	73.1	-	207.1
Interest expense, net	25.5	50.1	9.1	-	84.7
Impairment charges	-	13.8	-	-	13.8
Management (income) fees	-	(43.1)	43.1	-	-
	(136.0)	1,991.0	1,586.3	186.4	3,627.7
Income before income taxes	136.0	189.2	77.1	(186.4)	215.9
Provision for income taxes	7.1	71.2	-	-	78.3
Net income	128.9	118.0	77.1	(186.4)	137.6

Less: Net income attributable to noncontrolling interests and redeemable noncontrolling interests	-	(0.7)	(8.0)	-	(8.7)
Net income attributable to LifePoint Health, Inc.	\$ 128.9	\$ 117.3	\$ 69.1	\$ (186.4)	\$ 128.9

24

Table of Contents

LIFEPOINT HEALTH, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2016

Unaudited

LIFEPOINT HEALTH, INC.

Condensed Consolidating Balance Sheets

September 30, 2016

(In millions)

	Parent Issuer	Guarantors	Non- Guarantors	Eliminations	Consolidated
ASSETS					
Current assets:					
Cash and cash equivalents	\$ -	\$ 122.5	\$ 118.4	\$ -	\$ 240.9
Accounts receivable, net	-	516.4	380.4	-	896.8
Inventories	-	92.3	61.5	-	153.8
Prepaid expenses	0.2	39.0	23.8	-	63.0
Other current assets	-	19.3	39.2	-	58.5
	0.2	789.5	623.3	-	1,413.0
Property and equipment:					
Land	-	91.6	94.3	-	185.9
Buildings and improvements	-	1,866.8	872.6	-	2,739.4
Equipment	-	1,477.3	501.5	-	1,978.8
Construction in progress	-	109.5	100.8	-	210.3
	-	3,545.2	1,569.2	-	5,114.4
Accumulated depreciation	-	(1,656.0)	(410.9)	-	(2,066.9)
	-	1,889.2	1,158.3	-	3,047.5
Intangible assets, net	-	27.6	39.3	-	66.9
Investments in subsidiaries	2,464.7	-	-	(2,464.7)	-
Due from subsidiaries	2,608.0	-	-	(2,608.0)	-
Other long-term assets	16.6	31.7	32.1	-	80.4
Goodwill	-	1,466.4	254.6	-	1,721.0
Total assets	\$ 5,089.5	\$ 4,204.4	\$ 2,107.6	\$ (5,072.7)	\$ 6,328.8

LIABILITIES AND EQUITY

Current liabilities:

Accounts payable	\$ -	\$ 137.6	\$ 86.9	\$ -	\$ 224.5
Accrued salaries	0.3	123.0	87.2	-	210.5
Income taxes payable	26.4	-	-	-	26.4
Other current liabilities	40.2	145.2	115.3	-	300.7
Current maturities of long-term debt	17.5	0.5	3.5	-	21.5
	84.4	406.3	292.9	-	783.6
Long-term debt, net	2,755.3	47.6	86.3	-	2,889.2
Due to Parent	-	1,730.2	877.8	(2,608.0)	-
Deferred income taxes	44.5	-	-	-	44.5
Long-term portion of reserves for self-insurance claims	-	121.1	47.4	-	168.5
Other long-term liabilities	0.4	35.7	48.5	-	84.6
Total liabilities	2,884.6	2,340.9	1,352.9	(2,608.0)	3,970.4
Redeemable noncontrolling interests	-	-	105.7	-	105.7
Total LifePoint Health, Inc. stockholders' equity	2,204.9	1,861.9	602.8	(2,464.7)	2,204.9
Noncontrolling interests	-	1.6	46.2	-	47.8
Total equity	2,204.9	1,863.5	649.0	(2,464.7)	2,252.7
Total liabilities and equity	\$ 5,089.5	\$ 4,204.4	\$ 2,107.6	\$ (5,072.7)	\$ 6,328.8

Table of Contents

LIFEPOINT HEALTH, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2016

Unaudited

LIFEPOINT HEALTH, INC.

Condensed Consolidating Balance Sheets

December 31, 2015

(In millions)

	Parent Issuer	Guarantors	Non- Guarantors	Eliminations	Consolidated
ASSETS					
Current assets:					
Cash and cash equivalents	\$ -	\$ 200.9	\$ 83.1	\$ -	\$ 284.0
Accounts receivable, net	-	442.7	301.0	-	743.7
Inventories	-	75.1	52.6	-	127.7
Prepaid expenses	0.1	27.8	22.9	-	50.8
Other current assets	-	28.3	31.5	-	59.8
	0.1	774.8	491.1	-	1,266.0
Property and equipment:					
Land	-	74.0	88.8	-	162.8
Buildings and improvements	-	1,546.1	726.2	-	2,272.3
Equipment	-	1,344.0	423.8	-	1,767.8
Construction in progress	-	72.2	47.2	-	119.4
	-	3,036.3	1,286.0	-	4,322.3
Accumulated depreciation	-	(1,523.7)	(316.3)	-	(1,840.0)
	-	1,512.6	969.7	-	2,482.3
Intangible assets, net	-	30.2	40.4	-	70.6
Investments in subsidiaries	2,286.0	-	-	(2,286.0)	-
Due from subsidiaries	2,716.2	-	-	(2,716.2)	-
Other long-term assets	12.7	469.8	27.9	-	510.4
Goodwill	-	1,466.3	201.2	-	1,667.5
Total assets	\$ 5,015.0	\$ 4,253.7	\$ 1,730.3	\$ (5,002.2)	\$ 5,996.8
LIABILITIES AND EQUITY					
Current liabilities:					

Edgar Filing: LIFEPOINT HEALTH, INC. - Form 10-Q

Accounts payable	\$ -	\$ 91.2	\$ 73.1	\$ -	\$ 164.3
Accrued salaries	7.4	115.6	83.0	-	206.0
Income taxes payable	28.9	-	-	-	28.9
Other current liabilities	14.4	106.8	73.3	-	194.5
Current maturities of long-term debt	22.5	1.0	1.5	-	25.0
	73.2	314.6	230.9	-	618.7
Long-term debt, net	2,582.9	48.1	12.8	-	2,643.8
Due to Parent	-	2,044.4	671.8	(2,716.2)	-
Deferred income taxes	94.4	-	-	-	94.4
Long-term portion of reserves for self-insurance claims	-	104.5	50.2	-	154.7
Other long-term liabilities	0.6	25.4	46.8	-	72.8
Total liabilities	2,751.1	2,537.0	1,012.5	(2,716.2)	3,584.4
Redeemable noncontrolling interests	-	-	103.6	-	103.6
Total LifePoint Health, Inc. stockholders' equity	2,263.9	1,715.2	570.8	(2,286.0)	2,263.9
Noncontrolling interests	-	1.5	43.4	-	44.9
Total equity	2,263.9	1,716.7	614.2	(2,286.0)	2,308.8
Total liabilities and equity	\$ 5,015.0	\$ 4,253.7	\$ 1,730.3	\$ (5,002.2)	\$ 5,996.8

Table of Contents

LIFEPOINT HEALTH, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2016

Unaudited

LIFEPOINT HEALTH, INC.

Condensed Consolidating Statements of Cash Flows

For the Three Months Ended September 30, 2016

(In millions)

	Parent Issuer	Guarantors	Non- Guarantors	Eliminations	Consolidated
Cash flows from operating activities:					
Net income	\$ 39.5	\$ 50.9	\$ 15.9	\$ (65.1)	\$ 41.2
Adjustments to reconcile net income to net cash provided by operating activities:					
Equity in earnings of affiliates	(65.1)	-	-	65.1	-
Stock-based compensation	5.6	-	-	-	5.6
Depreciation and amortization	-	54.6	31.6	-	86.2
Amortization of physician minimum revenue guarantees	-	1.9	0.5	-	2.4
Amortization of debt issuance costs, discount and premium	1.3	-	-	-	1.3
Deferred income taxes	1.3	-	-	-	1.3
Reserve for self-insurance claims, net of payments	-	(1.9)	4.3	-	2.4
Increase (decrease) in cash from operating assets and liabilities, net of effects of acquisitions and divestitures:					
Accounts receivable	-	4.8	18.2	-	23.0
Inventories, prepaid expenses and other current assets	-	7.9	(2.0)	-	5.9
Accounts payable, accrued salaries and other current liabilities	25.5	(6.4)	(13.6)	-	5.5
Income taxes payable/receivable	2.6	-	-	-	2.6
Other	(1.1)	2.3	(1.0)	-	0.2

Edgar Filing: LIFEPOINT HEALTH, INC. - Form 10-Q

Net cash provided by operating activities	9.6	114.1	53.9	-	177.6
Cash flows from investing activities:					
Purchases of property and equipment	-	(59.9)	(43.5)	-	(103.4)
Acquisitions, net of cash acquired	-	-	(1.8)	-	(1.8)
Other	0.4	-	-	-	0.4
Net cash provided by (used in) investing activities	0.4	(59.9)	(45.3)	-	(104.8)
Cash flows from financing activities:					
Payments of borrowings	(4.4)	-	-	-	(4.4)
Repurchases of common stock	(101.4)	-	-	-	(101.4)
Change in intercompany balances with affiliates, net	95.8	(114.5)	18.7	-	-
Other	-	2.0	(2.3)	-	(0.3)
Net cash (used in) provided by financing activities	(10.0)	(112.5)	16.4	-	(106.1)
Change in cash and cash equivalents	-	(58.3)	25.0	-	(33.3)
Cash and cash equivalents at beginning of period	-	180.8	93.4	-	274.2
Cash and cash equivalents at end of period	\$ -	\$ 122.5	\$ 118.4	\$ -	\$ 240.9

Table of Contents

LIFEPOINT HEALTH, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2016

Unaudited

LIFEPOINT HEALTH, INC.

Condensed Consolidating Statements of Cash Flows

For the Three Months Ended September 30, 2015

(In millions)

	Parent Issuer	Guarantors	Non- Guarantors	Eliminations	Consolidated
Cash flows from operating activities:					
Net income	\$ 43.6	\$ 47.8	\$ 9.7	\$ (55.3)	\$ 45.8
Adjustments to reconcile net income to net cash provided by operating activities:					
Equity in earnings of affiliates	(55.3)	-	-	55.3	-
Stock-based compensation	7.4	-	-	-	7.4
Depreciation and amortization	-	44.1	26.1	-	70.2
Amortization of physician minimum revenue guarantees	-	2.4	0.6	-	3.0
Amortization of debt issuance costs, discount and premium	1.3	-	-	-	1.3
Impairment charge	-	2.2	-	-	2.2
Deferred income taxes	(7.7)	-	-	-	(7.7)
Reserve for self-insurance claims, net of payments	-	(4.2)	10.9	-	6.7
Increase (decrease) in cash from operating assets and liabilities, net of effects of acquisitions and divestitures:					
Accounts receivable	-	(0.1)	8.1	-	8.0
Inventories, prepaid expenses and other current assets	(0.1)	0.3	(1.0)	-	(0.8)
Accounts payable, accrued salaries and other current liabilities	21.6	11.5	(13.4)	-	19.7

Edgar Filing: LIFEPOINT HEALTH, INC. - Form 10-Q

Income taxes payable/receivable	19.2	-	-	-	19.2
Other	(0.5)	1.4	(1.6)	-	(0.7)
Net cash provided by operating activities	29.5	105.4	39.4	-	174.3
Cash flows from investing activities:					
Purchases of property and equipment	-	(37.0)	(22.2)	-	(59.2)
Acquisitions, net of cash acquired	-	(39.3)	(109.4)	-	(148.7)
Other	(0.7)	(1.5)	0.9	-	(1.3)
Net cash used in investing activities	(0.7)	(77.8)	(130.7)	-	(209.2)
Cash flows from financing activities:					
Payments of borrowings	(5.7)	-	-	-	(5.7)
Repurchases of common stock	(68.2)	-	-	-	(68.2)
Payments of debt financing costs	(0.2)	-	-	-	(0.2)
Proceeds from exercise of stock options	0.3	-	-	-	0.3
Change in intercompany balances with affiliates, net	45.0	(156.2)	111.2	-	-
Other	-	0.3	(1.2)	-	(0.9)
Net cash (used in) provided by in financing activities	(28.8)	(155.9)	110.0	-	(74.7)
Change in cash and cash equivalents	-	(128.3)	18.7	-	(109.6)
Cash and cash equivalents at beginning of period	-	316.7	106.1	-	422.8
Cash and cash equivalents at end of period	\$ -	\$ 188.4	\$ 124.8	\$ -	\$ 313.2

Table of Contents

LIFEPOINT HEALTH, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2016

Unaudited

LIFEPOINT HEALTH, INC.

Condensed Consolidating Statements of Cash Flows

For the Nine Months Ended September 30, 2016

(In millions)

	Parent Issuer	Guarantors	Non- Guarantors	Eliminations	Consolidated
Cash flows from operating activities:					
Net income	\$ 78.0	\$ 124.6	\$ 66.9	\$ (184.3)	\$ 85.2
Adjustments to reconcile net income to net cash (used in)					
provided by operating activities:					
Equity in earnings of affiliates	(184.3)	-	-	184.3	-
Stock-based compensation	23.0	-	-	-	23.0
Depreciation and amortization	-	160.7	96.4	-	257.1
Amortization of physician minimum revenue guarantees	-	6.2	1.3	-	7.5
Amortization of debt issuance costs, discount and premium	4.2	-	-	-	4.2
Debt transaction costs	22.0	-	-	-	22.0
Impairment charge	-	1.2	-	-	1.2
Deferred income taxes	(47.7)	-	-	-	(47.7)
Reserve for self-insurance claims, net of payments	-	13.7	14.0	-	27.7
Increase (decrease) in cash from operating assets and					
liabilities, net of effects of acquisitions and divestitures:					
Accounts receivable	-	(21.4)	(83.9)	-	(105.3)
	(0.1)	12.5	(7.4)	-	5.0

Edgar Filing: LIFEPOINT HEALTH, INC. - Form 10-Q

Inventories, prepaid expenses and other current assets					
Accounts payable, accrued salaries and other current liabilities	18.7	0.3	40.1	-	59.1
Income taxes payable/receivable	(2.5)	-	-	-	(2.5)
Other	(0.5)	2.6	(5.9)	-	(3.8)
Net cash (used in) provided by operating activities	(89.2)	300.4	121.5	-	332.7
Cash flows from investing activities:					
Purchases of property and equipment	-	(135.4)	(90.9)	-	(226.3)
Acquisitions, net of cash acquired	-	(118.2)	(2.1)	-	(120.3)
Other	(0.3)	(0.3)	-	-	(0.6)
Net cash used in investing activities	(0.3)	(253.9)	(93.0)	-	(347.2)
Cash flows from financing activities:					
Proceeds from borrowings	1,350.0	-	-	-	1,350.0
Payments of borrowings	(1,182.0)	-	-	-	(1,182.0)
Repurchases of common stock	(159.0)	-	-	-	(159.0)
Payments of debt financing costs	(30.0)	-	-	-	(30.0)
Proceeds from exercise of stock options	2.3	-	-	-	2.3
Change in intercompany balances with affiliates, net	108.2	(126.9)	18.7	-	-
Other	-	2.0	(11.9)	-	(9.9)
Net cash provided by (used in) financing activities	89.5	(124.9)	6.8	-	(28.6)
Change in cash and cash equivalents	-	(78.4)	35.3	-	(43.1)
Cash and cash equivalents at beginning of period	-	200.9	83.1	-	284.0
Cash and cash equivalents at end of period	\$ -	\$ 122.5	\$ 118.4	\$ -	\$ 240.9

Table of Contents

LIFEPOINT HEALTH, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2016

Unaudited

LIFEPOINT HEALTH, INC.

Condensed Consolidating Statements of Cash Flows

For the Nine Months Ended September 30, 2015

(In millions)

	Parent Issuer	Guarantors	Non- Guarantors	Eliminations	Consolidated
Cash flows from operating activities:					
Net income	\$ 128.9	\$ 118.0	\$ 77.1	\$ (186.4)	\$ 137.6
Adjustments to reconcile net income to net cash provided by operating activities:					
Equity in earnings of affiliates	(186.4)	-	-	186.4	-
Stock-based compensation	22.4	-	-	-	22.4
Depreciation and amortization	-	134.0	73.1	-	207.1
Amortization of physician minimum revenue guarantees	-	7.8	1.5	-	9.3
Amortization of debt issuance costs, discount and premium	3.8	-	-	-	3.8
Impairment charges	-	13.8	-	-	13.8
Deferred income taxes	3.1	-	-	-	3.1
Reserve for self-insurance claims, net of payments	-	(2.1)	17.6	-	15.5
Increase (decrease) in cash from operating assets and liabilities, net of effects of acquisitions and divestitures:					
Accounts receivable	-	3.2	32.0	-	35.2
	-	45.2	7.1	-	52.3

Edgar Filing: LIFEPOINT HEALTH, INC. - Form 10-Q

Inventories, prepaid expenses and other current assets					
Accounts payable, accrued salaries and other current liabilities	24.9	(24.2)	4.7	-	5.4
Income taxes payable/receivable	38.2	-	-	-	38.2
Other	(0.7)	-	(0.7)	-	(1.4)
Net cash provided by operating activities	34.2	295.7	212.4	-	542.3
Cash flows from investing activities:					
Purchases of property and equipment	-	(82.7)	(70.7)	-	(153.4)
Acquisitions, net of cash acquired	-	(44.5)	(130.0)	-	(174.5)
Proceeds from sale of hospital	-	18.8	-	-	18.8
Other	0.5	-	-	-	0.5
Net cash provided by (used in) investing activities	0.5	(108.4)	(200.7)	-	(308.6)
Cash flows from financing activities:					
Payments of borrowings	(11.3)	-	-	-	(11.3)
Repurchases of common stock	(102.0)	-	-	-	(102.0)
Payments of debt financing costs	(0.3)	-	-	-	(0.3)
Proceeds from exercise of stock options	11.1	-	-	-	11.1
Change in intercompany balances with affiliates, net	67.8	(61.6)	(6.2)	-	-
Other	-	0.7	(10.2)	-	(9.5)
Net cash used in financing activities	(34.7)	(60.9)	(16.4)	-	(112.0)
Change in cash and cash equivalents	-	126.4	(4.7)	-	121.7
Cash and cash equivalents at beginning of period	-	62.0	129.5	-	191.5
Cash and cash equivalents at end of period	\$ -	\$ 188.4	\$ 124.8	\$ -	\$ 313.2

Table of Contents

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations.

We recommend that you read this discussion together with our unaudited condensed consolidated financial statements and related notes included elsewhere in this report, as well as our Annual Report on Form 10-K for the year ended December 31, 2015 (the "2015 Annual Report on Form 10-K"). Unless otherwise indicated, all relevant financial and statistical information included herein relates to our consolidated operations. Additionally, unless the context indicates otherwise, LifePoint Health, Inc., and its subsidiaries are referred to in this section as "we," "our," or "us."

Forward-Looking Statements

We make forward-looking statements in this report, other reports and in statements we file with the Securities and Exchange Commission ("SEC") and/or release to the public. In addition, our senior management makes forward-looking statements orally to analysts, investors, the media and others. Broadly speaking, forward-looking statements include: projections of our revenues, net income, earnings per share, capital expenditures, cash flows, debt repayments, interest rates, operating statistics and data or other financial items; efforts to reduce the cost of providing healthcare while increasing quality; descriptions of plans or objectives of our management for future operations, services or growth plans including acquisitions, divestitures, business strategies, core strategies and other initiatives, including our relationship with Duke University Health System, Inc. through Duke LifePoint Healthcare; interpretations of Medicare and Medicaid laws and regulations and their effect on our business; and descriptions of assumptions underlying or relating to any of the foregoing.

In this report, for example, we make forward-looking statements, including statements discussing our expectations about: future financial performance and condition; future liquidity and capital resources; future cash flows; existing debt; changes in depreciation and amortization expenses; our business strategy and operating philosophy; effects of competition in our markets; costs of providing care to our patients; our compliance with new and existing laws and regulations as well as costs and benefits associated with compliance; the impact of national healthcare reform; other income from electronic health records ("EHR"); anticipated capital expenditures, including routine projects, investments in information systems and capital projects related to recent acquisitions and the expectation that capital commitments could be a significant component of future acquisitions; timeframes for completion of capital projects; implementation of supply chain management and revenue cycle functions; accounting estimates and the impact of accounting methodologies; industry and general economic trends; patient shifts to lower cost healthcare plans which generally provide lower reimbursement; participation in the healthcare exchanges and the impact of the increasing use of narrow networks and tiered networks; reimbursement changes, including policy considerations and changes resulting from state budgetary restrictions; patient volumes and related revenues; claims and legal actions relating to professional liabilities; governmental investigations and voluntary self-disclosures; and physician recruiting, employment and retention.

Forward-looking statements discuss matters that are not historical facts. Because they discuss future events or conditions, forward-looking statements often include words such as "can," "could," "may," "should," "believe," "will," "would," "expect," "project," "estimate," "seek," "anticipate," "intend," "target," "continue," "predict" or similar expressions. You should not unduly rely on forward-looking statements, which give our expectations about the future and are not guarantees. Forward-looking statements speak only as of the date they are made. We operate in a continually changing business environment, and new risk factors emerge from time to time. We cannot predict such new risk factors nor can we assess the impact, if any, of such new risk factors on our business or the extent to which any factor or combination of factors may cause actual results to differ materially from those expressed or implied by any forward-looking

statement. We do not undertake any obligation to update our forward-looking statements to reflect events or circumstances after the date of this document or to reflect the occurrence of unanticipated events.

There are several factors, some beyond our control that could cause results to differ significantly from our expectations. Some of these factors, as well as other factors such as market, operational, liquidity, interest rate and other risks, are described in Part I, Item 1A. Risk Factors and Part II, Item 7A. Quantitative and Qualitative Disclosures about Market Risk of the 2015 Annual Report on Form 10-K. Any factor described in this report and in the 2015 Annual Report on Form 10-K could by itself, or together with one or more factors, adversely affect our business, results of operations and/or financial condition. There may be factors not described in this report or in the 2015 Annual Report on Form 10-K that could also cause results to differ from our expectations.

Table of Contents

Overview

We own and operate community hospitals, regional health systems, physician practices, outpatient centers, and post-acute facilities. At September 30, 2016, on a consolidated basis, we operated 72 hospital campuses in 22 states throughout the United States (“U.S.”), having a total of 9,424 licensed beds. We generate revenues primarily through patient services offered at our facilities. We generated revenues of \$1,585.7 million and \$1,309.5 million during the three months ended September 30, 2016 and 2015, respectively, and \$4,758.8 million and \$3,843.6 million during the nine months ended September 30, 2016 and 2015, respectively. During the three months ended September 30, 2016 and 2015, respectively, we derived 44.4% and 46.9%, of our revenues, collectively, from the Medicare and Medicaid programs and 44.6% and 46.3% during the nine months ended September 30, 2016 and 2015, respectively. Payments made to our facilities pursuant to the Medicare and Medicaid programs for services rendered rarely exceed our costs for such services. As a result, we rely largely on payments made by private or commercial payors, together with certain limited services provided to Medicare recipients, to generate an operating profit. The healthcare industry continues to endure a period where the costs of providing care are rising faster than reimbursement rates from government or private commercial payors. This places a premium on efficient operation, the ability to reduce or control costs and the need to leverage the benefits of our organization across all of our facilities.

Competitive and Structural Environment

The environment in which our facilities operate is extremely competitive. Our hospitals face competition from other acute care hospitals, including larger tertiary hospitals located in larger markets and/or affiliated with universities; specialty hospitals that focus on one or a small number of very lucrative service lines but that are not required to operate emergency departments; stand-alone centers at which surgeries or diagnostic tests can be performed; and physicians on the medical staffs of our hospitals. In many cases, our competitors focus on the service lines that offer the highest margins. By doing so, our competitors can potentially draw the best-paying business out of our hospitals. This, in turn, can reduce the overall operating profit of our hospitals as we are often obligated to offer service lines that operate at a loss or that have much lower profit margins. We continue to see the shift of increasingly complex procedures from the inpatient to the outpatient setting and have also seen growth in the general shift of lower acuity procedures to physician offices and other non-hospital outpatient settings. These trends have, to some extent, offset our efforts to improve equivalent admission rates at many of our hospitals.

Our hospitals also face extreme competition in their efforts to recruit and retain physicians on their medical staffs. It is widely recognized that the U.S. has a shortage of physicians in certain practice areas, including primary care physicians and specialists such as cardiologists, oncologists, urologists and orthopedists, in various areas of the country. This fact, and our ability to overcome these shortages, is directly relevant to our growth strategies because cardiologists, oncologists, urologists and orthopedists are often the physicians in highest demand in communities where our hospitals are located. Larger tertiary medical centers are acquiring physician practices and employing physicians in some of our communities. While physicians in these practices may continue to be members of the medical staffs of our hospitals, they may be less likely to refer patients to our hospitals over time.

We believe other key factors in our competition for patients is the quality of our patient care and the perception of that quality in the communities where our facilities are located, which may be influenced by, among other things, the technology, service lines and capital improvements made at our facilities and by the skills and experience of our non-physician employees involved in patient care.

In addition to competitive concerns, many of our communities are experiencing slow growth, and in some cases, population losses. We believe this trend has occurred mainly as a result of recent challenging economic conditions

because the economies in the non-urban communities in which our facilities primarily operate are often dependent on a small number of larger employers, especially manufacturing or other facilities. This causes the economies of our communities to be more sensitive to economic downturns and slower to rebound when the overall U.S. economy improves. In addition, other economic factors, including, potentially, self-rationing of healthcare services, have made it more difficult to increase the number of patients who seek care at many of our facilities.

Table of Contents

Business Strategy

In order to achieve growth in patient volumes, revenues and profitability given the competitive and structural environment, we continue to focus our business strategy on the following:

- Measurement and improvement of quality of patient care and perceptions of such quality in communities where our facilities are located;
- Targeted recruiting of primary care physicians and physicians in key specialties;
- Retention of physicians and efforts to improve physician satisfaction, including employing a greater number of primary care physicians as well as physicians in certain specialties;
- Retention and, where needed, recruitment of non-physician employees involved in patient care and efforts to improve employee satisfaction;
- Targeted investments in new technologies, new service lines and capital improvements at our facilities;
- Improvements in management of expenses and revenue cycle;
- Negotiation of improved reimbursement rates with non-governmental payors;
- Strategic growth through acquisition and integration of hospitals and other healthcare facilities where valuations are attractive and we can identify opportunities for improved financial performance through our management or ownership; and
- Developing strategic partnerships with not-for-profit healthcare providers to achieve growth in new regions.

As part of our ongoing efforts to further manage costs and improve the results of our revenue cycle, we have partnered with a third party to provide certain nonclinical business functions, including payroll processing, supply chain management and revenue cycle functions. We believe this model of sharing centralized resources to support common business functions across multi-facility enterprises provides us efficiencies and is the most cost effective approach to managing these nonclinical business functions.

Regulatory Environment

Our business and our facilities are highly regulated, and the penalties for noncompliance can be severe. We are required to comply with extensive, complicated and overlapping government laws and regulations at the federal, state and local levels. These laws and regulations govern every aspect of how our hospitals conduct their operations, from what service lines must be offered in order to be licensed as an acute care hospital, to whether our hospitals may employ physicians, and to how (and whether) our hospitals may receive payments pursuant to the Medicare and Medicaid programs. The failure to comply with these laws and regulations can result in severe penalties including criminal penalties, civil sanctions, and the loss of our ability to receive reimbursements through the Medicare and Medicaid programs.

Not only are our facilities heavily regulated, but the rules, regulations and laws to which they are subject often change, with little or no notice, and are often interpreted and applied differently by various regulatory agencies with authority to enforce such requirements. Each change or conflicting interpretation may require our facilities to make changes in space usage, equipment, personnel or services, and may also require that standard operating policies and procedures be re-written and re-implemented. The cost of complying with such laws and regulations is a significant component of our overall expenses. Further, this expense has grown in recent periods because of new regulatory requirements and the severity of the penalties associated with non-compliance. Management anticipates that compliance expenses will continue to grow in the foreseeable future. The healthcare industry has seen a number of ongoing investigations related to patient referrals, physician recruiting and employment practices, cost reporting and billing practices, medical necessity of inpatient admissions, physician office leasing, laboratory and home healthcare services, physician ownership of hospitals and other healthcare providers, and joint ventures involving hospitals and physicians.

Hospitals continue to be one of the primary focal areas of the Office of Inspector General (“OIG”), the Department of Justice (“DOJ”) and other governmental fraud and abuse programs.

Table of Contents

Health Care Reform

The Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act of 2010 (collectively the “Affordable Care Act”) dramatically altered the U.S. healthcare system and was intended to decrease the number of uninsured Americans and reduce the overall cost of healthcare. The Affordable Care Act attempts to achieve these goals by, among other things, requiring most Americans to obtain health insurance, providing additional funding for Medicaid in states that choose to expand their programs, reducing Medicare and Medicaid disproportionate share hospital payments to providers, expanding the Medicare program’s use of value-based purchasing programs, tying hospital payments to the satisfaction of certain quality criteria, bundling payments to hospitals and other providers, and instituting certain private health insurance reforms.

The net effect of the Affordable Care Act on our business is subject to numerous variables, including the law’s complexity, lack of complete implementing regulations and interpretive guidance, gradual implementation and possible amendment, as well as the uncertainty as to the extent to which states will choose to expand their Medicaid programs and the extent to which individuals will elect coverage. We are also unable to predict with a high level of precision how providers, payors, employers and other market participants will continue to respond to the various reform provisions. As a result, we are unable to predict with any certainty the net effect on our business, financial condition or results of operations of the expected increases in insured individuals using our facilities, the reductions in government healthcare reimbursement spending, and numerous other provisions of the Affordable Care Act that may affect us. In addition, there have been and likely will continue to be a number of legal challenges to various provisions of the Affordable Care Act, and several bills have been and may continue to be introduced in Congress to delay, defund or repeal implementation of or amend significant provisions of the Affordable Care Act. The results of such litigation and legislative efforts may impact our business in the future. During 2015, and continuing during 2016, and primarily as a result of the expansion of health insurance coverage, we experienced an increase in revenues from providing care to certain previously uninsured individuals. Although we expect this trend to continue, the future impact and timing of such expansion remains difficult to predict for the reasons discussed above, will be gradual and may not offset scheduled decreases in reimbursement.

Medicare and Medicaid Reimbursement

Medicare payment methodologies have been, and are expected to continue to be, revised significantly based on cost containment and policy considerations. The Centers for Medicare and Medicaid Services (“CMS”) has already implemented some of the Medicare reimbursement reductions required by the Affordable Care Act, and these revisions will likely become more frequent and significant as more of the Affordable Care Act’s changes and cost-saving measures become effective. Additionally, the Middle Class Tax Relief and Job Creation Act of 2012 and the American Taxpayer Relief Act of 2012 (“ATRA”) require further reductions in Medicare payments, and the Budget Control Act of 2011 imposed a 2% reduction in Medicare spending effective as of April 1, 2013, which was extended by the Bipartisan Budget Act of 2015 (the “BBA”), through 2025.

On August 22, 2016, CMS published its hospital inpatient prospective payment system (“IPPS”) final rule for federal fiscal year (“FFY”) 2017, which began on October 1, 2016. Among other things, the rule provides an operating payment rate increase of approximately 0.95% for hospitals that successfully report the quality measures for the Hospital Inpatient Quality Reporting (“IQR”) Program and are meaningful EHR users. The rate increase is based on a hospital

market basket increase of 2.7%, which is reduced by (i) a multi-factor productivity adjustment of 0.3%, (ii) a 0.75% reduction required by the Affordable Care Act, and (iii) a 1.5% documentation and coding recoupment adjustment required by the American Taxpayer Relief Act of 2012 (“ATRA”) and increased by (iv) a permanent adjustment of 0.2% to prospectively remove the 0.2% reduction in payment rates that was implemented in FFY 2014 to offset the estimated increase in IPPS expenditures resulting from the Medicare program’s “two midnight rule” and (v) a temporary one-time prospective increase of 0.6% to address the effects of the 0.2% reduction to the rate for the two-midnight rule for FFYs 2014, 2015, and 2016. The documentation and coding recoupment adjustment is the last of a series of adjustments that CMS was required to make by ATRA in order to recover \$11 billion by FFY 2017 to fully recoup documentation and coding overpayments that Congress believes occurred from FFY 2008 through 2013 solely as the result of the transition to the Medicare severity diagnosis related group system that began in FFY 2008. Hospitals that do not successfully report quality data under the IQR Program will be subject to a 25% reduction of the hospital market basket increase prior to the application of any applicable statutory adjustments. Hospitals that are not meaningful EHR users are also subject to an additional 75% reduction of the hospital market basket increase.

Table of Contents

In addition to establishing the payment rate update, the IPPS final rule for FFY 2017 also makes a number of other changes to the Medicare program's IPPS. Among other things, the final rule makes updates to the measures used in the IQR, Hospital Value-Based Purchasing, Hospital Acquired Conditions Reduction, and Hospital Readmissions Reduction Programs and would distribute almost \$6.0 billion in uncompensated care payments to hospitals in FFY 2017, which would be a decrease of approximately \$400 million from the FFY 2016 amount. The uncompensated care funds will be distributed based on insured low income days, which include inpatient days for patients eligible for Medicaid and inpatient days for patients entitled to Medicare and Supplemental Security Income. Overall, CMS estimates that under the final rule, total Medicare spending on inpatient hospital services, including capital, will increase by about \$746 million in FFY 2017.

On July 14, 2016, CMS published its hospital outpatient prospective payment system ("OPPS") proposed rule for calendar year ("CY") 2017, which begins on January 1, 2017. Among other things, the proposed rule provides for a payment rate increase of 1.55% for hospitals that meet the reporting requirements of the Medicare Hospital Outpatient Quality Reporting ("OQR") Program and a payment rate decrease of 0.45% for hospitals that do not. The proposed rate increase is based on a proposed hospital market basket increase of 2.8%, which is reduced by a multi-factor productivity adjustment of 0.5% and an additional 0.75% reduction required by the Affordable Care Act. In addition to updating the OPPS payment rate, the proposed rule would also, among other things, remove the pain management dimension of the Hospital Consumer Assessment of Healthcare Providers and Systems survey for the purposes of the Medicare Hospital Value-Based Purchasing Program, add seven measures to the OQR Program for the CY 2020 payment determination and subsequent years, remove six procedures from the Medicare inpatient-only procedure list, establish a 90-day EHR reporting period in 2016 for all eligible professionals, eligible hospitals and critical access hospitals ("CAHs"), and reduce certain reporting requirements for eligible hospitals and CAHs attesting under the Medicare EHR Incentive Program. Overall, CMS estimates that under the proposed rule, OPPS payments to providers, including estimated spending for pass-through payments, would increase by approximately 1.6% in CY 2017.

In addition to those changes, the OPPS proposed rule for CY 2016 also includes several provisions regarding the implementation of Section 603 of the BBA, which, effective as of January 1, 2017, limits OPPS reimbursement for items and services that are furnished by certain off-campus outpatient provider-based departments ("off-campus PBDs") of hospitals. Under the proposed rule, CMS would continue to make OPPS payments to off-campus PBDs that were billing Medicare as hospital departments under the OPPS on or prior to November 1, 2015 ("grandfathered PBDs"). However, grandfathered PBDs would generally not be allowed to relocate, and grandfathered status would only be given to items and services that are part of the same clinical families of services, such as advanced imaging, diagnostic tests, general surgery, and radiation oncology, that were furnished and billed by the grandfathered PBD prior to November 2, 2015. Any items and services that are not part of a clinical family of services furnished and billed by the grandfathered PBD prior to November 2, 2015, would not be eligible for OPPS payment. In addition to grandfathered PBDs, CMS would continue to reimburse all items and services that are furnished in a dedicated emergency department of a hospital, as such term is defined for the purposes of the Emergency Medical Treatment and Active Labor Act, regardless of whether the items and services are emergency items and services, and all items and services that are furnished in off-campus PBDs that are located within 250 yards of a remote location of a hospital, which is a facility that is either created or acquired by a hospital for the purpose of furnishing inpatient hospital services under the name, ownership, and financial and administrative control of the hospital, under the OPPS. Under the proposed rule, all items and services not provided at a grandfathered or otherwise excepted PBD and all items and services that are not part of a clinical family of services furnished and billed by a grandfathered PBD prior

to November 2, 2015, would generally be paid by CMS under the Medicare Physician Fee Schedule (“MPFS”).

Table of Contents

With respect to payment under the MPFS for items and services that are subject to the reimbursement limitations set forth in Section 603 of the BBA, in the proposed rule, CMS stated that while it intends to eventually provide a mechanism for non-grandfathered or excepted off-campus PBDs to bill and receive payment for those items and services, given the complexities of the Medicare payment and claims processing systems, new payment processes cannot be developed prior to January 1, 2017. As a result, CMS is proposing that for CY 2017, payment by the Medicare program for items and services that are subject to the payment limitations set forth in Section 603 of the BBA will be made to the treating physician or practitioners at the non-facility rate under the MPFS, and Medicare will not make any separate facility payments to the applicable hospital for those items and services. CMS stated that in the alternative, a hospital could, assuming the location at issue could meet the applicable conditions for coverage or payment, elect to have non-grandfathered or otherwise excepted off-campus PBDs enroll in the Medicare program as another provider/supplier type, such as an ambulatory surgery center or a physician group practice, and receive payment under the Medicare ambulatory surgical center payment system or MPFS. CMS solicited comments on potential system changes and the development of new payment mechanisms that would allow an off-campus PBD to bill for items and services that are subject to the payment limitations set forth in Section 603 of the BBA under the MPFS beginning in CY 2018. The CMS actuary has estimated that the implementation of Section 603 of the BBA will save the Medicare program approximately \$500 million in CY 2017. We cannot predict whether the OPFS proposed rule for CY 2017 will be implemented in whole or in part, or, if implemented, the impact that the OPFS proposed rule for CY 2017 would have on our results of operations.

On July 25, 2016, CMS released a proposed rule that, among other things, would create a new bundled payment model for cardiac care and that would expand the existing Comprehensive Care for Joint Replacement (“CJR”) model to certain hip surgeries. Under the proposed rule, the hospital in which a patient is admitted for care for a heart attack, bypass surgery, or surgical hip/femur treatment would be accountable for the cost and quality of care provided to Medicare beneficiaries during their inpatient stay and for a period of 90 days thereafter. Once the bundled payment models are fully in effect, participating hospitals would be paid a fixed target price for each episode of care, with hospitals that deliver higher quality care receiving a higher target price. At the end of each model performance year of the five year test period, CMS would compare actual spending for the episode (total expenditures for related services under Medicare Parts A and B) to the target price that reflects episode quality for the responsible hospital. Depending on the hospital’s quality and episode spending performance, the hospital would either receive an additional payment from the Medicare program or would be required to repay Medicare a portion of the episode spending. CMS has proposed to implement the heart attack and bypass surgery bundled payment models in 98 metropolitan statistical areas (“MSAs”) that would be randomly selected in the future and the expansion of the CJR model in the 67 MSAs that were originally selected for the CJR model, which includes some MSAs where the Company has facilities. In addition, the proposed rule would establish a cardiac rehabilitation incentive payment program that would be implemented in 90 MSAs and would test the impact of providing incentive payments to hospitals based on Medicare beneficiary utilization of cardiac rehabilitation and intensive cardiac rehabilitation services in the 90 day period following the beneficiary’s discharge from the hospital for a heart attack or bypass surgery. We cannot predict whether the proposed rule will be implemented in whole or in part, or, if implemented, the impact that the proposed rule would have on our results of operations.

“Two Midnight Rule”

On May 4, 2016, CMS temporarily suspended performance by the Beneficiary and Family Centered Care (“BFCC”) Quality Improvement Organizations’ (“QIOs”) of initial patient status reviews to determine the appropriateness of Part A payments for short stay inpatient hospital claims. CMS implemented the temporary suspension after becoming aware of inconsistencies in the BFCC-QIOs’ application of the Two-Midnight Rule. CMS had indicated that the reviews would resume during the third quarter of 2016 after the BFCC-QIOs had completed retraining on the Two-Midnight Rule, re-reviewed all claims that they had denied in connection with the Two-Midnight Rule medical review process since October 2015, and performed any provider outreach and education that was required. The BFCC-QIOs have completed those activities, and CMS lifted the temporary suspension effective as of September 12, 2016. As a result, the BFCC-QIOs have resumed their initial patient status reviews of short stays in acute care inpatient hospitals, long-term care hospitals and inpatient psychiatric facilities.

Table of Contents

Physician Services

Physician services are reimbursed under the MPFS system, under which CMS has assigned a national relative value unit (“RVU”) to most medical procedures and services that reflects the various resources required by a physician to provide the services relative to all other services. Each RVU is calculated based on a combination of work required in terms of time and intensity of effort for the service, practice expense (overhead) attributable to the service and malpractice insurance expense attributable to the service. These three elements are each modified by a geographic adjustment factor to account for local practice costs then aggregated. The aggregated amount has historically been multiplied by a conversion factor that accounts for inflation and targeted growth in Medicare expenditures (as calculated by the sustainable growth rate (“SGR”)) to arrive at the payment amount for each service. The SGR has generally resulted in significant reductions to payments made under the MPFS, and, since 2003, Congress has passed multiple legislative acts delaying application of the SGR to the MPFS.

On April 16, 2015, President Obama signed the Medicare Access and CHIP Reauthorization Act of 2015 (“MACRA”) into law. Among other things, MACRA replaced the SGR formula with new systems for establishing the annual updates to payments made under the MPFS. Under MACRA, the MPFS payment rates were increased by 0.5% for CY 2016 and will be increased by 0.5% a year from 2017 through 2019. MPFS payment rates would then remain at their CY 2019 levels through CY 2025. Beginning in CY 2019, amounts paid to individual physicians would be subject to adjustment through the CMS Quality Payment Program (“QPP”) that rewards the delivery of high-quality patient care. The QPP operates through two avenues: the Advanced Alternative Payment Model (“Advanced APM”) program for eligible clinicians or groups under the MPFS and the Merit-Based Incentive Payment System (“MIPS”). Physicians who participate in the MIPS program, which would essentially consolidate the existing Physician Quality Reporting System, the Value-Based Modifier, and the Meaningful Use of EHR incentive programs, would be subject to positive, zero, or negative performance adjustments depending on how the physician’s performance compared to a performance threshold. In addition, from CY 2019 through CY 2024, MACRA provides an additional \$500 million per year for an additional performance adjustment for physicians who participate in MIPS and achieve exceptional performance. Physicians who participate in an Advanced APM program and receive a substantial amount of their revenue from an alternative payment model would receive, from CY 2019 through 2024, a lump-sum payment equal to 5% of their Medicare payments in the prior year for services paid under the MPFS. Beginning in CY 2026, MPFS payment rates for physicians participating in an Advanced APM program would be increased by 0.75% a year. Payments for other providers would be increased by 0.25% per year.

On July 15, 2016, CMS published the MPFS proposed rule for CY 2017. Among other things, the proposed rule implements the 0.5% increase in MPFS payment rates for CY 2017 that is specified by MACRA. In addition, the proposed rule makes a number of coding and payment changes to better identify and value primary care, care management, and cognitive services, such as making separate payments for certain existing Current Procedural Terminology (“CPT”) codes describing non-face-to-face prolonged evaluation and management services, revaluing existing CPT codes describing face-to-face prolonged services, making separate payments using new codes to describe comprehensive assessment and care planning for patients with cognitive impairment, making separate payments using new codes to recognize the increased resource costs of furnishing visits to patients with mobility-related impairments, making separate payments using new codes to pay primary care practices that use

interprofessional care management resources to treat patients with behavioral health conditions, and making separate payments for codes describing chronic care management for patients with greater complexity. The proposed rule would also add several codes, including codes for end-stage renal disease and advanced care planning services, to the list of services eligible to be furnished by telehealth, expand the Medicare program's diabetes prevention program beginning in CY 2018, require healthcare providers and suppliers to be screened and enrolled in Medicare in order to contract with a Medicare Advantage organization, and further implement Appropriate Use Criteria for advanced diagnostic imaging services.

On October 14, 2016, CMS released a final rule implementing MACRA. Among other things, the final rule establishes the QPP and its MIPS and Advanced APM pathways. The final rule also designates CY 2017 as a transition year for the QPP and allows physicians to pick the pace of participation for the first performance period that begins on January 1, 2017. Under the final rule, eligible clinicians will have three flexible options to submit data to the MIPS and a fourth option to join Advanced APMs in order to become qualified Advanced APM participants ("QPs"), which would ensure that they do not receive a negative payment adjustment in CY 2019. The final rule also reduces the amount of measures that are required to be reported to MIPS, the amount of risk that providers must accept when participating in an Advanced APM, and the minimum performance thresholds that must be met to avoid a payment penalty. CMS estimates that for the CY 2017 performance period, between 592,000 and 642,000 eligible clinicians will be required to participate in MIPS and between 70,000 and 120,000 clinicians will become QPs through participation in Advanced APMs. CMS has also indicated that given the complexity of MACRA, the QPP will likely evolve over multiple years and that the policies implementing MACRA and the QPP will be further refined and developed through a "staged approach" in the future.

Table of Contents

Adoption of Electronic Health Records

The Health Information Technology for Economic and Clinical Health Act (the “HITECH Act”), which was enacted into law as part of the American Recovery and Reinvestment Act of 2009, includes provisions designed to increase the use of EHR by both physicians and hospitals. EHR meaningful use objectives and measures that hospitals and physicians must meet in order to qualify for incentive payments will be implemented in three stages. We strive to comply with the EHR meaningful use requirements of the HITECH Act in time to qualify for the maximum available incentive payments. Our compliance has and will continue to result in significant costs including business process changes, professional services focused on successfully designing and implementing our EHR solutions along with costs associated with the hardware and software components of the project. As we complete our full implementation of certified EHR technology, our EHR incentive payments will decline and ultimately end. We currently estimate that at a minimum total costs incurred to comply will be recovered through the total EHR incentive payments over the projected lifecycle of this initiative.

Privacy and Security Requirements and Administrative Simplification Provisions

We are subject to the administrative simplification provisions of the Health Insurance Portability and Accountability Act of 1996 (“HIPAA”) which require the use of uniform electronic data transmission standards for healthcare claims and payment transactions submitted or received electronically. These provisions are intended to encourage electronic commerce in the healthcare industry.

Additionally, we are subject to the privacy, security and breach notification regulations promulgated under HIPAA and the HITECH Act, which are designed to protect the confidentiality, availability and integrity of protected health information and establish an array of patient rights with respect to such information. The HIPAA privacy, security and breach notification regulations apply to covered entities, which include health plans, healthcare clearinghouses, and healthcare providers that conduct certain standard transactions (such as billing insurance) electronically. In addition, certain provisions of the privacy, security and breach notification regulations apply to business associates, which are entities that perform certain functions or activities on behalf of covered entities that require access to or the use or disclosure of protected health information. In certain circumstances, a covered entity may be held liable for the actions of its business associate if the Department of Health and Human Services (“HHS”) determines an agency relationship exists between the covered entity and the business associate under federal agency law.

In March 2016, HHS announced the start of phase II of the HIPAA audit program, which will consist of a combination of remote desk audits and comprehensive onsite evaluations of covered entities and business associates and will focus on compliance with the HIPAA privacy, security and breach notification rules. HHS officials have also indicated that these audits could lead to compliance reviews or enforcement actions against organizations that fail to respond appropriately to audit requests or for which an audit reveals significant compliance issues.

Table of Contents

Revenue Sources

Our facilities generate revenues by providing healthcare services to our patients. Depending upon the patient's medical insurance coverage, we are paid for these services by governmental Medicare and Medicaid programs, commercial insurance, including managed care organizations, and directly by the patient. The amounts we are paid for providing healthcare services to our patients vary depending upon the payor. Governmental payors generally pay significantly less than the hospital's customary charges for the services provided. Insured patients are generally not responsible for any difference between customary hospital charges and the amounts received from commercial insurance payors. However, insured patients are responsible for payments not covered by insurance, such as exclusions, deductibles and co-payments.

Revenues from governmental payors, such as Medicare and Medicaid, are controlled by complex rules and regulations that stipulate the amount a hospital is paid for providing healthcare services. We must comply with these rules and regulations to continue to be eligible to participate in the Medicare and Medicaid programs. These rules and regulations are subject to frequent changes as a result of legislative and administrative action and annual payment adjustments on both the federal and the state levels.

Revenues from health maintenance organizations ("HMOs"), preferred provider organizations ("PPOs") and other private insurers are subject to contracts and other arrangements that require us to discount the amounts we customarily charge for healthcare services. These discounted arrangements often limit our ability to increase charges in response to increasing costs. We actively negotiate with these payors in an effort to maintain or increase the pricing of our healthcare services; however, we have no control over patients switching their healthcare coverage to a payor with which we have negotiated less favorable reimbursement rates. In recent years, an increasing number of our patients have moved to lower cost healthcare coverage plans, and such plans generally provide lower reimbursement rates and require patients to pay an increased portion of the costs of care through deductibles, co-payments or exclusions. Additionally, plans purchased through the healthcare exchanges are increasingly using narrow and tiered networks that limit beneficiary provider choices. If we provide services when we are not a participating provider in the network, it can result in higher patient responsibility amounts that a patient may not have the ability to pay or may choose not to pay. We expect these trends to continue in the coming years.

Self-pay revenues are primarily generated through the treatment of uninsured patients. Beginning in 2014, our self-pay revenues began to decrease due largely to a shift from self-pay to Medicaid and HMOs, PPOs and other private insurers for a portion of our patient population, which primarily was a result of healthcare reform and the expansion of Medicaid coverage in certain of the states in which we operate. These reductions partially offset trends our hospitals have experienced in recent years, including increases in self-pay revenues due to a combination of broad economic factors, including high levels of unemployment in many of our markets and increasing numbers of individuals and employers who purchase insurance plans with high deductibles and high co-payments.

To provide for accounts receivable that could become uncollectible in the future, we establish an allowance for doubtful accounts to reduce the carrying value of such receivables to their estimated net realizable value. Our provision for doubtful accounts serves to reduce our reported revenues.

Table of Contents

Results of Operations

The following definitions apply throughout the remaining portion of Management's Discussion and Analysis of Financial Condition and Results of Operations:

Admissions. Represents the total number of patients admitted to our hospitals and used by management and investors as a general measure of inpatient volume.

bps. Basis points.

Consolidated. Consolidated information includes the results of our health support center, our same-hospital operations and the results of our recent acquisitions. Additionally, consolidated information includes the results of our hospitals that have previously been disposed.

Effective tax rate. Provision for income taxes as a percentage of income before income taxes less net income attributable to noncontrolling interests and redeemable noncontrolling interests.

Emergency room visits. Represents the total number of hospital-based emergency room visits.

Equivalent admissions. Management and investors use equivalent admissions as a general measure of combined inpatient and outpatient volume. We compute equivalent admissions by multiplying admissions (inpatient volume) by the outpatient factor (the sum of gross inpatient revenue and gross outpatient revenue and then dividing the resulting amount by gross inpatient revenue). The equivalent admissions computation "equates" outpatient revenue to the volume measure (admissions) used to measure inpatient volume resulting in a general measure of combined inpatient and outpatient volume.

Medicare case mix index. Refers to the acuity or severity of illness of an average Medicare patient at our hospitals.

N/A. Not applicable.

Net revenue days outstanding. We compute net revenue days outstanding by dividing our accounts receivable net of allowance for doubtful accounts, by our revenue per day. Our revenue per day is calculated by dividing our quarterly revenues by the number of calendar days in the quarter.

Outpatient surgeries. Outpatient surgeries are those surgeries that do not require admission to our hospitals.

Revenues. Revenues represent amounts recognized from all payors for the delivery of healthcare services, net of contractual discounts and the provision for doubtful accounts.

Same-hospital. Same-hospital information includes the results of our health support center and the same 64 hospitals operated during the three months ended September 30, 2016 and 2015, and the same 63 hospitals operated during the nine months ended September 30, 2016 and 2015. Same-hospital information excludes our hospitals that have previously been disposed.

Table of Contents

For the Three Months Ended September 30, 2016 and 2015

Operating Results Summary

The following table summarizes the results of operations for the three months ended September 30, 2016 and 2015 (dollars in millions):

	Three Months Ended September 30, 2016		2015	
	Amount	% of Revenues	Amount	% of Revenues
Revenues before provision for doubtful accounts	\$ 1,821.1	114.8 %	\$ 1,522.3	116.3 %
Provision for doubtful accounts	235.4	14.8	212.8	16.3
Revenues	1,585.7	100.0	1,309.5	100.0
Salaries and benefits	755.0	47.6	626.2	47.8
Supplies	262.0	16.5	205.7	15.7
Other operating expenses	384.1	24.2	313.2	23.9
Other income	(3.4)	(0.2)	(8.3)	(0.6)
Depreciation and amortization	86.2	5.5	70.2	5.3
Interest expense, net	36.9	2.3	28.2	2.2
Impairment charges	-	-	2.2	0.2
	1,520.8	95.9	1,237.4	94.5
Income before income taxes	64.9	4.1	72.1	5.5
Provision for income taxes	23.7	1.5	26.3	2.0
Net income	41.2	2.6	45.8	3.5
Less: Net income attributable to noncontrolling interests and redeemable noncontrolling interests	(1.7)	(0.1)	(2.2)	(0.2)
Net income attributable to LifePoint Health, Inc.	\$ 39.5	2.5 %	\$ 43.6	3.3 %

Revenues

Edgar Filing: LIFEPOINT HEALTH, INC. - Form 10-Q

The following table presents the components of revenues for the three months ended September 30, 2016 and 2015 (dollars in millions):

	Three Months Ended September 30,				
	2016	2015	Increase	% Increase	
Consolidated:					
Revenues before provision for doubtful accounts	\$ 1,821.1	\$ 1,522.3	\$ 298.8	19.6 %	
Provision for doubtful accounts	235.4	212.8	22.6	10.6	
Revenues	\$ 1,585.7	\$ 1,309.5	\$ 276.2	21.1	
Same-hospital:					
Revenues before provision for doubtful accounts	\$ 1,495.8	\$ 1,479.6	\$ 16.2	1.1 %	
Provision for doubtful accounts	209.0	207.9	1.1	0.5	
Revenues	\$ 1,286.8	\$ 1,271.7	\$ 15.1	1.2	

Table of Contents

Our revenues before provision for doubtful accounts by payor and approximate percentages of revenues were as follows for the three months ended September 30, 2016 and 2015 (in millions):

	Three Months Ended September 30, 2016		2015	
	Amount	% of Revenues	Amount	% of Revenues
Medicare	\$ 473.4	29.9 %	\$ 390.5	29.8 %
Medicaid	230.1	14.5	223.7	17.1
HMOs, PPOs and other private insurers	863.2	54.4	674.0	51.5
Self-pay	221.0	13.9	204.9	15.7
Other	33.4	2.1	29.2	2.2
Revenues before provision for doubtful accounts	1,821.1	114.8	1,522.3	116.3
Provision for doubtful accounts	(235.4)	(14.8)	(212.8)	(16.3)
Revenues	\$ 1,585.7	100.0 %	\$ 1,309.5	100.0 %

Certain changes have been made to our classification of historical sources of revenues. Specifically, we changed the classification of certain revenues related to our owned physician practices from HMOs, PPOs and other private insurers to the respective payor classifications, as appropriate. This change had no impact on our historical results of operations.

Our revenues per equivalent admission on a consolidated and same-hospital basis were as follows for the three months ended September 30, 2016 and 2015:

	Three Months Ended September 30,		Increase	% Increase
	2016	2015		
Revenues per equivalent admission - consolidated	\$ 8,740	\$ 8,270	\$ 470	5.7
Revenues per equivalent admission - same-hospital	\$ 8,578	\$ 8,329	\$ 249	3.0

Revenues Before Provision for Doubtful Accounts

The following table shows the key drivers of our revenues before provision for doubtful accounts for the three months ended September 30, 2016 and 2015:

	Three Months Ended		Increase (Decrease)	% Increase (Decrease)
	September 30, 2016	2015		
Consolidated:				
Admissions	67,955	58,754	9,201	15.7
Equivalent admissions	181,426	158,332	23,094	14.6
Medicare case mix index	1.48	1.43	0.05	3.5
Average length of stay (days)	4.9	4.9	-	-
Inpatient surgeries	19,329	16,731	2,598	15.5
Outpatient surgeries	69,998	62,234	7,764	12.5
Total surgeries	89,327	78,965	10,362	13.1
Emergency room visits	431,222	378,302	52,920	14.0
Outpatient factor	2.67	2.70	(0.03)	(1.1)
Same-hospital:				
Admissions	54,968	56,508	(1,540)	(2.7)
Equivalent admissions	150,008	152,685	(2,677)	(1.8)
Medicare case mix index	1.45	1.43	0.02	1.4
Average length of stay (days)	4.9	4.9	-	-
Inpatient surgeries	15,156	16,064	(908)	(5.7)
Outpatient surgeries	58,777	60,064	(1,287)	(2.1)
Total surgeries	73,933	76,128	(2,195)	(2.9)
Emergency room visits	361,648	368,972	(7,324)	(2.0)
Outpatient factor	2.73	2.70	0.03	1.0

Table of Contents

For the three months ended September 30, 2016, our consolidated revenues before provision for doubtful accounts increased \$298.8 million, or 19.6%, to \$1,821.1 million as compared to the same period last year primarily as a result of our recent acquisitions and an increase in our same-hospital revenues before provision for doubtful accounts of \$16.2 million, or 1.1%, to \$1,495.8 million as compared to the same period last year. The increase in our same-hospital revenues before provision for doubtful accounts was primarily driven by higher contracted rates from HMOs, PPOs and other private insurers, in addition to higher acuity services, as evidenced by an increase in the Medicare case mix index. For the three months ended September 30, 2016, our same-hospital revenues per equivalent admission increased 3.0% as compared to the same period last year. This increase was partially offset by a 1.8% decrease in our same-hospital equivalent admissions as compared to the same period last year, primarily as a result of a 2.0% decrease in emergency room visits and a 2.9% decrease in total surgeries.

Provision for Doubtful Accounts

The following table summarizes the key drivers and key indicators of our provision for doubtful accounts for the three months ended September 30, 2016 and 2015 (dollars in millions):

	Three Months Ended September 30,				Increase	% Increase
	2016	% of	2015	% of	(Decrease)	(Decrease)
		Revenues		Revenues		
Consolidated:						
Related key indicators:						
Charity care write-offs	\$ 29.0	1.8 %	\$ 22.3	1.7 %	\$ 6.7	29.6 %
Self-pay revenues, net of charity care write-offs and uninsured discounts	\$ 221.0	13.9 %	\$ 204.9	15.7 %	\$ 16.1	7.9 %
Net revenue days outstanding (at end of period)	53.3	N/A	54.1	N/A	(0.8)	(1.5) %
Same-hospital:						
Related key indicators:						
Charity care write-offs	\$ 20.4	1.6 %	\$ 21.3	1.7 %	\$ (0.9)	(4.4) %
Self-pay revenues, net of charity						

care write-offs and uninsured discounts	\$ 195.8	15.2	%	\$ 199.5	15.7	%	\$ (3.7)	(1.9)	%
Net revenue days outstanding (at end of period)	51.5	N/A		52.6	N/A		(1.1)	(2.1)	%

Our provision for doubtful accounts relates principally to amounts due from patients included in our self-pay population and other amounts such as co-payments and deductibles due from patients included in other payor categories. For the three months ended September 30, 2016, our provision for doubtful accounts increased by \$22.6 million, or 10.6%, to \$235.4 million on a consolidated basis and was comparable to the same period last year on a same-hospital basis increasing by only \$1.1 million, or 0.5%, to \$209.0 million. The provision and allowance for doubtful accounts are critical accounting estimates and are further discussed in Part II, Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations, "Critical Accounting Estimates," in the 2015 Annual Report on Form 10-K.

Certain changes have been made to our classification of historical sources of revenues. Specifically, we changed the classification of certain revenues related to our owned physician practices from HMOs, PPOs and other private insurers to the respective payor classifications, as appropriate. This change had no impact on our historical results of operations.

Our net revenue days outstanding at September 30, 2016 improved on a consolidated basis to 53.3 days as compared to 54.1 days at September 30, 2015. Additionally, on a same hospital basis, our net revenue days outstanding at September 30, 2016 improved to 51.5 days as compared to 52.6 days at September 30, 2015.

Table of Contents

Expenses and Other Income

Salaries and Benefits

The following table summarizes our salaries and benefits, man-hours per equivalent admission and salaries and benefits per equivalent admission for the three months ended September 30, 2016 and 2015:

	Three Months Ended September 30,		Three Months Ended September 30,		Increase	% Increase
	2016	% of Revenues	2015	% of Revenues		
Salaries and benefits (dollars in millions)	\$ 755.0	47.6 %	\$ 626.2	47.8 %	\$ 128.8	20.6 %
Man-hours per equivalent admission	112	N/A	109	N/A	3	2.8 %
Salaries and benefits per equivalent admission	\$ 4,161	N/A	\$ 3,956	N/A	\$ 205	5.2 %

For the three months ended September 30, 2016, our salaries and benefits expense increased to \$755.0 million, or 20.6%, as compared to \$626.2 million for the same period last year primarily a result of our recent acquisitions and the impact of an increasing number of employed physicians and their related support staff.

Supplies

The following table summarizes our supplies and supplies per equivalent admission for the three months ended September 30, 2016 and 2015:

	Three Months Ended September 30,		Three Months Ended September 30,		Increase	% Increase
	2016	% of Revenues	2015	% of Revenues		
Supplies (dollars in millions)	\$ 262.0	16.5 %	\$ 205.7	15.7 %	\$ 56.3	27.4 %

Edgar Filing: LIFEPOINT HEALTH, INC. - Form 10-Q

Supplies per equivalent admission \$ 1,444 N/A \$ 1,297 N/A \$ 147 11.3 %

For the three months ended September 30, 2016, our supplies expense increased to \$262.0 million, or 27.4%, as compared to \$205.7 million for the same period last year primarily as a result of our recent acquisitions as well as an increase in our same-hospital supplies per equivalent admission as a result of a higher utilization of more expensive supplies in areas such as orthopedics, pharmacy and oncology. These increases were partially offset by improvements as a result of generic drug substitutions, monitoring of physician preference items and growth within our group purchasing organization.

Other Operating Expenses

The following table summarizes our other operating expenses for the three months ended September 30, 2016 and 2015 (dollars in millions):

	Three Months Ended September 30,							
	2016	% of Revenues	2015	% of Revenues	Increase (Decrease)	% Increase (Decrease)		
Professional fees	\$ 70.9	4.5 %	\$ 50.5	3.9 %	\$ 20.4	40.3 %		
Utilities	30.7	1.9	25.9	2.0	4.8	18.7		
Repairs and maintenance	45.7	2.9	35.1	2.7	10.6	30.1		
Rents and leases	17.7	1.1	13.4	1.0	4.3	32.4		
Insurance	13.0	0.8	13.6	1.0	(0.6)	(4.7)		
Physician recruiting	4.1	0.3	5.4	0.4	(1.3)	(23.1)		
Contract services	113.7	7.2	94.8	7.2	18.9	19.9		
Non-income taxes	44.6	2.8	35.2	2.7	9.4	26.7		
Other	43.7	2.7	39.3	3.0	4.4	11.2		
	\$ 384.1	24.2 %	\$ 313.2	23.9 %	\$ 70.9	22.6 %		

Table of Contents

For the three months ended September 30, 2016, our other operating expenses increased to \$384.1 million, or 22.6%, as compared to \$313.2 million for the same period last year as a result of our recent acquisitions as well as increases in our same-hospital professional fees and contract services. As a result of a continued shortage of physicians in many of our communities, we have experienced increasing professional fees in areas such as anesthesiology and hospitalists. Our same-hospital contract services expenses have increased primarily as a result of higher business office collection efforts arising from an increase in our same-hospital revenues as well as additional contract services associated with an increasing number of employed physicians.

Other Income

We recognize EHR incentive payments received or anticipated to be received under the HITECH Act as other income when our eligible hospitals and physician practices have demonstrated meaningful use of certified EHR technology for the applicable period and when the cost report information for the full cost report year that determines the final calculation of the EHR incentive payment is available. For the three months ended September 30, 2016, we recognized \$3.4 million in Medicare and Medicaid EHR incentive payments, collectively, as compared to \$8.3 million recognized in the same period last year. As we complete our full implementation of certified EHR technology, our EHR incentive payments will decline and ultimately end.

Depreciation and Amortization

For the three months ended September 30, 2016, our depreciation and amortization expense increased by \$16.0 million, or 22.7% to \$86.2 million, or 5.5% of revenues, as compared to \$70.2 million, or 5.3% of revenues for the same period last year. Our depreciation and amortization expense increased primarily as a result of our recent acquisitions as well as increases in our spending related to information systems due to various initiatives and requirements, including compliance with the HITECH Act. Additionally, we incurred approximately \$1.5 million, \$0.9 million net of income taxes, or \$0.02 loss per diluted share, of additional depreciation expense during the three months ended September 30, 2016 as a result of accelerating the depreciation on one of our hospital campuses as further discussed in Note 10 to our accompanying unaudited condensed consolidated financial statements included elsewhere in this report. We anticipate that our depreciation and amortization expense will continue to increase in future periods as a result of these factors in addition to the impact of capital expenditure commitments associated with our recent acquisitions.

Interest Expense, Net

Our interest expense increased by \$8.7 million, or 30.7% to \$36.9 million for the three months ended September 30, 2016 as compared to \$28.2 million for the same period last year. The increase in our interest expense is primarily attributable to an increase in our weighted average total debt outstanding during the three months ended September 30, 2016 as compared to the same period last year. On December 4, 2015, we issued in a public offering \$500.0 million aggregate principal amount of 5.875% unsecured senior notes due December 1, 2023 (the "5.875% Senior

Notes”). Additionally, on May 26, 2016, we issued in a private placement \$500.0 million aggregate principal amount of 5.375% unsecured senior notes due May 1, 2024 (the “5.375% Senior Notes”) and used the proceeds, in part, to redeem all \$400.0 million aggregate principal amount of our outstanding 6.625% unsecured senior notes due October 1, 2020 (the “6.625% Senior Notes”) on June 13, 2016. For a further discussion of our debt and corresponding interest rates, see “Liquidity and Capital Resources — Debt” and Note 7 to our accompanying unaudited condensed consolidated financial statements included elsewhere in this report.

Impairment Charges

During the three months ended September 30, 2015, we recognized an additional impairment charge of \$2.2 million, \$1.4 million net of income taxes, or \$0.03 loss per diluted share, related to the finalization of the net working capital settlement in connection with the divestiture of a hospital.

Provision for Income Taxes

Our provision for income taxes was \$23.7 million, or 1.5% of revenues, for the three months ended September 30, 2016, as compared to \$26.3 million, or 2.0% of revenues, for the same period last year. The decrease in the provision for income taxes for the three months ended September 30, 2016 was primarily attributable to a decrease in our income before income taxes for the three months ended September 30, 2016, as compared to the same period last year. Additionally, our effective tax rate decreased slightly to 37.5% for the three months ended September 30, 2016, as compared to 37.6% for the same period last year.

Table of Contents

For the Nine Months Ended September 30, 2016 and 2015

Operating Results Summary

The following table summarizes the results of operations for the nine months ended September 30, 2016 and 2015 (dollars in millions):

	Nine Months Ended September 30, 2016		2015	
	Amount	% of Revenues	Amount	% of Revenues
Revenues before provision for doubtful accounts	\$ 5,438.2	114.3 %	\$ 4,443.7	115.6 %
Provision for doubtful accounts	679.4	14.3	600.1	15.6
Revenues	4,758.8	100.0	3,843.6	100.0
Salaries and benefits	2,281.0	47.9	1,844.2	48.0
Supplies	793.3	16.7	596.6	15.5
Other operating expenses	1,179.3	24.8	915.5	23.8
Other income	(19.8)	(0.4)	(34.2)	(0.9)
Depreciation and amortization	257.1	5.3	207.1	5.4
Interest expense, net	112.8	2.4	84.7	2.2
Debt transaction costs	22.0	0.5	-	-
Impairment charges	1.2	-	13.8	0.4
	4,626.9	97.2	3,627.7	94.4
Income before income taxes	131.9	2.8	215.9	5.6
Provision for income taxes	46.7	1.0	78.3	2.0
Net income	85.2	1.8	137.6	3.6
Less: Net income attributable to noncontrolling interests and redeemable noncontrolling interests	(7.2)	(0.2)	(8.7)	(0.2)
Net income attributable to LifePoint Health, Inc.	\$ 78.0	1.6 %	\$ 128.9	3.4 %

Revenues

The following table presents the components of revenues for the nine months ended September 30, 2016 and 2015 (dollars in millions):

	Nine Months Ended September 30,				
	2016	2015	Increase	%	
Consolidated:					
Revenues before provision for doubtful accounts	\$ 5,438.2	\$ 4,443.7	\$ 994.5	22.4	%
Provision for doubtful accounts	679.4	600.1	79.3	13.2	
Revenues	\$ 4,758.8	\$ 3,843.6	\$ 915.2	23.8	
Same-hospital:					
Revenues before provision for doubtful accounts	\$ 4,462.4	\$ 4,347.0	\$ 115.4	2.7	%
Provision for doubtful accounts	608.9	581.6	27.3	4.7	
Revenues	\$ 3,853.5	\$ 3,765.4	\$ 88.1	2.3	

Table of Contents

Our revenues before provision for doubtful accounts by payor and approximate percentages of revenues were as follows for the nine months ended September 30, 2016 and 2015 (in millions):

	Nine Months Ended September 30, 2016		2015	
	Amount	% of Revenues	Amount	% of Revenues
Medicare	\$ 1,423.9	29.9 %	\$ 1,145.1	29.8 %
Medicaid	698.7	14.7	634.8	16.5
HMOs, PPOs and other private insurers	2,588.4	54.4	2,020.7	52.6
Self-pay	626.8	13.2	552.0	14.3
Other	100.4	2.1	91.1	2.4
Revenues before provision for doubtful accounts	5,438.2	114.3	4,443.7	115.6
Provision for doubtful accounts	(679.4)	(14.3)	(600.1)	(15.6)
Revenues	\$ 4,758.8	100.0 %	\$ 3,843.6	100.0 %

Certain changes have been made to our classification of historical sources of revenues. Specifically, we changed the classification of certain revenues related to our owned physician practices from HMOs, PPOs and other private insurers to the respective payor classifications, as appropriate. This change had no impact on our historical results of operations.

Our revenues per equivalent admission on a consolidated and same-hospital basis were as follows for the nine months ended September 30, 2016 and 2015:

	Nine Months Ended September 30,		Increase	% Increase
	2016	2015		
Revenues per equivalent admission - consolidated	\$ 8,830	\$ 8,353	\$ 477	5.7
Revenues per equivalent admission - same-hospital	\$ 8,714	\$ 8,415	\$ 299	3.6

Revenues Before Provision for Doubtful Accounts

Edgar Filing: LIFEPOINT HEALTH, INC. - Form 10-Q

The following table shows the key drivers of our revenues before provision for doubtful accounts for the nine months ended September 30, 2016 and 2015:

	Nine Months Ended		Increase (Decrease)	% Increase (Decrease)
	September 30, 2016	2015		
Consolidated:				
Admissions	205,937	177,255	28,682	16.2
Equivalent admissions	538,937	460,154	78,783	17.1
Medicare case mix index	1.49	1.42	0.07	4.9
Average length of stay (days)	4.9	4.9	-	-
Inpatient surgeries	58,311	48,797	9,514	19.5
Outpatient surgeries	212,388	180,807	31,581	17.5
Total surgeries	270,699	229,604	41,095	17.9
Emergency room visits	1,275,030	1,105,605	169,425	15.3
Outpatient factor	2.62	2.60	0.02	0.8
Same-hospital:				
Admissions	165,740	172,159	(6,419)	(3.7)
Equivalent admissions	442,194	447,441	(5,247)	(1.2)
Medicare case mix index	1.47	1.42	0.05	3.5
Average length of stay (days)	5.0	5.0	-	-
Inpatient surgeries	45,530	47,114	(1,584)	(3.4)
Outpatient surgeries	175,929	175,116	813	0.5
Total surgeries	221,459	222,230	(771)	(0.3)
Emergency room visits	1,063,648	1,074,223	(10,575)	(1.0)
Outpatient factor	2.67	2.60	0.07	2.7

Table of Contents

For the nine months ended September 30, 2016, our consolidated revenues before provision for doubtful accounts increased \$994.5 million, or 22.4%, to \$5,438.2 million as compared to the same period last year primarily as a result of our recent acquisitions and an increase in our same-hospital revenues before provision for doubtful accounts of \$115.4 million, or 2.7%, to \$4,462.4 million as compared to the same period last year. The increase in our same-hospital revenues before provision for doubtful accounts was primarily driven by higher acuity services, as evidenced by an increase in the Medicare case mix index, in addition to higher contracted rates from HMOs, PPOs and other private insurers. For the nine months ended September 30, 2016, our same-hospital revenues per equivalent admission increased 3.6% as compared to the same period last year. This increase was partially offset by a 1.2% decrease in our same-hospital equivalent admissions as compared to the same period last year, primarily as a result of a 1.0% decrease in emergency room visits and a 0.3% decrease in total surgeries.

Provision for Doubtful Accounts

The following table summarizes the key drivers and key indicators of our provision for doubtful accounts for the nine months ended September 30, 2016 and 2015 (dollars in millions):

	Nine Months Ended September 30,								
	2016	% of Revenues		2015	% of Revenues		Increase (Decrease)	% Increase (Decrease)	
Consolidated:									
Related key indicators:									
Charity care write-offs	\$ 99.2	2.1 %		\$ 67.2	1.7 %		\$ 32.0	47.5 %	
Self-pay revenues, net of charity care write-offs and uninsured discounts	\$ 626.8	13.2 %		\$ 552.0	14.3 %		\$ 74.8	13.6 %	
Net revenue days outstanding (at end of period)	53.3	N/A		54.1	N/A		(0.8)	(1.5) %	
Same-hospital:									
Related key indicators:									
Charity care write-offs	\$ 63.5	1.6 %		\$ 63.5	1.7 %		\$ -	- %	
Self-pay revenues, net of charity care write-offs and uninsured discounts	\$ 558.1	14.5 %		\$ 538.0	14.3 %		\$ 20.1	3.7 %	

Net revenue days outstanding (at end of period)	51.5	N/A	52.6	N/A	(1.1)	(2.1)	%
--	------	-----	------	-----	-------	-------	---

Our provision for doubtful accounts relates principally to amounts due from patients included in our self-pay population and other amounts such as co-payments and deductibles due from patients included in other payor categories. For the nine months ended September 30, 2016, our provision for doubtful accounts increased by \$79.3 million, or 13.2%, to \$679.4 million on a consolidated basis and increased by \$27.3 million, or 4.7%, to \$608.9 million on a same-hospital basis as compared to the same period last year. Additionally, our same-hospital self-pay revenues increased \$20.1 million, or 3.7%, to \$558.1 million as compared to the same period last year. The provision and allowance for doubtful accounts are critical accounting estimates and are further discussed in Part II, Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations, "Critical Accounting Estimates," in the 2015 Annual Report on Form 10-K.

Certain changes have been made to our classification of historical sources of revenues. Specifically, we changed the classification of certain revenues related to our owned physician practices from HMOs, PPOs and other private insurers to the respective payor classifications, as appropriate. This change had no impact on our historical results of operations.

Our net revenue days outstanding at September 30, 2016 improved on a consolidated basis to 53.3 days as compared to 54.1 days at September 30, 2015. Additionally on a same hospital basis, our net revenue days outstanding at September 30, 2016 improved to 51.5 days as compared to 52.6 days at September 30, 2015.

Table of Contents

Expenses and Other Income

Salaries and Benefits

The following table summarizes our salaries and benefits, man-hours per equivalent admission and salaries and benefits per equivalent admission for the nine months ended September 30, 2016 and 2015:

	Nine Months Ended September 30,		%		Increase	%
	2016	% of Revenues	2015	% of Revenues		
Salaries and benefits (dollars in millions)	\$ 2,281.0	47.9 %	\$ 1,844.2	48.0 %	\$ 436.8	23.7 %
Man-hours per equivalent admission	113	N/A	110	N/A	3	2.7 %
Salaries and benefits per equivalent admission	\$ 4,232	N/A	\$ 4,009	N/A	\$ 223	5.6 %

For the nine months ended September 30, 2016, our salaries and benefits expense increased to \$2,281.0 million, or 23.7%, as compared to \$1,844.2 million for the same period last year primarily a result of our recent acquisitions and the impact of an increasing number of employed physicians and their related support staff.

Supplies

The following table summarizes our supplies and supplies per equivalent admission for the nine months ended September 30, 2016 and 2015:

	Nine Months Ended September 30,		%		Increase	%
	2016	% of Revenues	2015	% of Revenues		
Supplies (dollars in millions)	\$ 793.3	16.7 %	\$ 596.6	15.5 %	\$ 196.7	33.0 %
Supplies per equivalent admission	\$ 1,472	N/A	\$ 1,296	N/A	\$ 176	13.6 %

For the nine months ended September 30, 2016, our supplies expense increased to \$793.3 million, or 33.0%, as compared to \$596.6 million for the same period last year primarily as a result of our recent acquisitions as well as an increase in our same-hospital supplies per equivalent admission as a result of a higher utilization of more expensive

supplies in areas such as orthopedics, pharmacy and oncology. These increases were partially offset by improvements as a result of generic drug substitutions, monitoring of physician preference items and growth within our group purchasing organization.

Other Operating Expenses

The following table summarizes our other operating expenses for the nine months ended September 30, 2016 and 2015 (dollars in millions):

	Nine Months Ended September 30,				Increase (Decrease)	% Increase (Decrease)
	2016	% of Revenues	2015	% of Revenues		
Professional fees	\$ 206.4	4.3 %	\$ 144.1	3.7 %	\$ 62.3	43.2 %
Utilities	84.7	1.8	71.1	1.8	13.6	19.2
Repairs and maintenance	137.1	2.9	103.5	2.7	33.6	32.4
Rents and leases	52.6	1.1	39.4	1.0	13.2	33.4
Insurance	65.5	1.4	42.6	1.1	22.9	53.7
Physician recruiting	13.0	0.3	16.4	0.4	(3.4)	(20.5)
Contract services	350.2	7.4	275.2	7.2	75.0	27.2
Non-income taxes	133.1	2.8	102.0	2.7	31.1	30.6
Other	136.7	2.8	121.2	3.2	15.5	12.7
	\$ 1,179.3	24.8 %	\$ 915.5	23.8 %	\$ 263.8	28.8 %

Table of Contents

For the nine months ended September 30, 2016, our other operating expenses increased to \$1,179.3 million, or 28.8%, as compared to \$915.5 million for the same period last year as a result of our recent acquisitions as well as increases in our same-hospital professional fees, contract services and insurance expenses. As a result of a continued shortage of physicians in many of our communities, we have experienced increasing professional fees in areas such as anesthesiology and hospitalists. Our same-hospital contract services expenses have increased primarily as a result of higher business office collection efforts arising from an increase in our same-hospital revenues as well as additional contract services associated with an increasing number of employed physicians. We experienced an increase in our insurance expenses for the nine months ended September 30, 2016 as a result of recording an accrual for loss contingencies for cardiology-related legal proceedings as described further in Note 10 to our accompanying unaudited condensed consolidated financial statements included elsewhere in this report.

Additionally, during the second quarter of 2016, one of our largest facilities experienced the loss of certain key physicians, including our decision to part ways with the physician leader of a key service line. This resulted in additional professional fees and recruiting expenses. Furthermore, during the second quarter of 2016, we incurred additional contract services expense due to the implementation of a new physician billing system in order to ensure accuracy and to help achieve long-term synergies at one of our recently acquired facilities.

Other Income

We recognize EHR incentive payments received or anticipated to be received under the HITECH Act as other income when our eligible hospitals and physician practices have demonstrated meaningful use of certified EHR technology for the applicable period and when the cost report information for the full cost report year that determines the final calculation of the EHR incentive payment is available. For the nine months ended September 30, 2016, we recognized \$19.8 million in Medicare and Medicaid EHR incentive payments, collectively, as compared to \$34.2 million recognized in the same period last year. As we complete our full implementation of certified EHR technology, our EHR incentive payments will decline and ultimately end.

Depreciation and Amortization

For the nine months ended September 30, 2016, our depreciation and amortization expense increased by \$50.0 million, or 24.1% to \$257.1 million, or 5.3% of revenues, as compared to \$207.1 million, or 5.4% of revenues for the same period last year. Our depreciation and amortization expense increased primarily as a result of our recent acquisitions as well as increases in our spending related to information systems due to various initiatives and requirements, including compliance with the HITECH Act. Additionally, we incurred approximately \$4.7 million, \$2.9 million net of income taxes, or \$0.07 loss per diluted share, of additional depreciation expense during the nine months ended September 30, 2016 as a result of accelerating the depreciation on one of our hospital campuses as further discussed in Note 10 to our accompanying unaudited condensed consolidated financial statements included elsewhere in this report. We anticipate that our depreciation and amortization expense will continue to increase in future periods as a result of these factors in addition to the impact of capital expenditure commitments associated with our recent acquisitions.

Interest Expense, Net

Our interest expense increased by \$28.1 million, or 33.2% to \$112.8 million for the nine months ended September 30, 2016 as compared to \$84.7 million for the same period last year. The increase in our interest expense is primarily attributable to an increase in our weighted average total debt outstanding during the nine months ended September 30, 2016 as compared to the same period last year. On December 4, 2015, we issued \$500.0 million aggregate principal amount of 5.875% Senior Notes. Additionally, on May 26, 2016, we issued \$500.0 million aggregate principal amount of 5.375% Senior Notes and used the proceeds, in part, to redeem all \$400.0 million aggregate principal amount of our outstanding 6.625% Senior Notes on June 13, 2016. For a further discussion of our debt and corresponding interest rates, see “Liquidity and Capital Resources — Debt” and Note 7 to our accompanying unaudited condensed consolidated financial statements included elsewhere in this report.

Table of Contents

Debt Transaction Costs

On June 10, 2016, we repaid the outstanding balances of the prior senior secured term loan facility (the “Prior Term Facility”) and the senior secured incremental term loans (the “Incremental Term Loans”) under our prior senior secured credit agreement with, among others, Citibank, N.A. as administrative agent, and the lenders party thereto (the “Prior Credit Agreement”) with the proceeds from the \$700.0 million senior secured term loan facility (the “Term Facility”) under our senior secured credit agreement with, among others, Citibank, N.A. as administrative agent, and the lenders party thereto (the “Senior Credit Agreement”). Additionally, on May 26, 2016, we issued \$500.0 million aggregate principal amount of 5.375% Senior Notes and used the proceeds, in part, to redeem all \$400.0 million aggregate principal amount of our outstanding 6.625% Senior Notes on June 13, 2016. These transactions are more fully discussed in Note 7 to our accompanying unaudited condensed consolidated financial statements included elsewhere in this report. In connection with these debt transactions, we recognized debt transaction costs of approximately \$22.0 million, \$13.7 million net of income taxes, or \$0.31 loss per diluted share, during the nine months ended September 30, 2016. The debt transaction costs include the write-offs of previously capitalized issuance costs and new non-capital costs related to our various debt transactions entered into during the second quarter of 2016.

Impairment Charges

During the nine months ended September 30, 2016, we recognized an impairment charge of \$1.2 million, \$0.8 million net of income taxes, or \$0.02 loss per diluted share, related to the write-off of certain capital assets which we have determined are no longer a necessary component of our ongoing information technology strategy.

Additionally, during the nine months ended September 30, 2015, we recognized impairment charges totaling \$13.8 million, \$8.9 million net of income taxes, or \$0.19 loss per diluted share, related to the divestitures of four hospitals. The impairment charges included the write-down of property, equipment, allocated goodwill and certain other assets to their estimated fair values.

Provision for Income Taxes

Our provision for income taxes was \$46.7 million, or 1.0% of revenues, for the nine months ended September 30, 2016, as compared to \$78.3 million, or 2.0% of revenues, for the same period last year. The decrease in the provision for income taxes for the nine months ended September 30, 2016 was primarily attributable to a decrease in our income before income taxes for the nine months ended September 30, 2016, as compared to the same period last year. Additionally, our effective tax rate decreased slightly to 37.4% for the nine months ended September 30, 2016, as compared to 37.8% for the same period last year.

Liquidity and Capital Resources

Liquidity

Our primary sources of liquidity are cash flows provided by our operations and our debt borrowings. On June 10, 2016, we entered into our Senior Credit Agreement, comprised of the \$700.0 million Term Facility and a \$600.0 million senior secured revolving credit facility (the “Revolving Facility”), and used the proceeds from the Term Facility to repay outstanding amounts under our Prior Credit Agreement. Additionally, on May 26, 2016, we issued \$500.0 million aggregate principal amount of 5.375% Senior Notes and used the proceeds, in part, to redeem all \$400.0 million aggregate principal amount of our outstanding 6.625% Senior Notes on June 13, 2016. These transactions are more fully discussed in Note 7 to our accompanying unaudited condensed consolidated financial statements included elsewhere in this report. We believe that our internally generated cash flows and amounts available for borrowing under our Senior Credit Agreement will be adequate to service existing debt, finance internal growth and fund capital expenditures and small to mid-size hospital acquisitions over the next twelve months and into the foreseeable future prior to maturity dates of our outstanding debt. Certain larger hospital acquisitions may, however, require additional financing.

Table of Contents

The following table presents summarized cash flow information for the three and nine months ended September 30, 2016 and 2015 (in millions):

	Three Months Ended		Nine Months Ended	
	September 30, 2016	September 30, 2015	September 30, 2016	September 30, 2015
Net cash provided by operating activities	\$ 177.6	\$ 174.3	\$ 332.7	\$ 542.3
Less: Purchases of property and equipment	(103.4)	(59.2)	(226.3)	(153.4)
Free operating cash flow	74.2	115.1	106.4	388.9
Acquisitions, net of cash acquired	(1.8)	(148.7)	(120.3)	(174.5)
Proceeds from sale of hospital	-	-	-	18.8
Proceeds from borrowings	-	-	1,350.0	-
Payments of borrowings	(4.4)	(5.7)	(1,182.0)	(11.3)
Repurchases of common stock	(101.4)	(68.2)	(159.0)	(102.0)
Payments of debt financing costs	-	(0.2)	(30.0)	(0.3)
Proceeds from exercise of stock options	-	0.3	2.3	11.1
Other	0.1	(2.2)	(10.5)	(9.0)
Net change in cash and cash equivalents	\$ (33.3)	\$ (109.6)	\$ (43.1)	\$ 121.7

The non-GAAP metric of free operating cash flow is an important liquidity measure for us. Our computation of free operating cash flow consists of net cash flows provided by continuing operations less cash flows used for the purchase of property and equipment. We believe that free operating cash flow is useful to investors and management as a measure of the ability of our business to generate cash and to repay and incur additional debt, and make strategic investments. However, free operating cash flow does not fully reflect our ability to deploy generated cash for discretionary spending, as it does not reflect required debt payments or other fixed obligations. Computations of free operating cash flow may differ from company to company. Therefore, free operating cash flow should be used as a complement to, and in conjunction with, our condensed consolidated statements of cash flows presented in our unaudited condensed consolidated financial statements included elsewhere in this report.

Our cash flows provided by operating activities for the three months ended September 30, 2016 as compared to the same period last year were positively impacted by improvements in the amount and timing of cash collections of outstanding accounts receivable, partially offset by an increase in the amount and timing of payments for income taxes and other accrued expenses.

Our cash flows provided by operating activities for the nine months ended September 30, 2016 as compared to the same period last year were negatively impacted by the timing of cash collections of outstanding accounts receivable primarily as a result of the normal build-up of accounts receivable at certain of our recently acquired facilities where

we did not acquire accounts receivable. Additionally, our cash flows provided by operating activities for the nine months ended September 30, 2016 as compared to the same period last year were negatively impacted by increases in the amount and timing of payments for income taxes and interest and a decrease in the amount and timing of receipts related to certain Medicaid DSH programs. These decreases were partially offset by decreases in the amount and timing of payments for accounts payable and accrued salaries.

Table of Contents

Capital Expenditures

We continue to make significant, targeted investments at our hospitals to add new technologies, modernize facilities and expand the services available. These investments should assist in our efforts to attract and retain physicians, to offset outmigration of patients and to make our hospitals more desirable to our employees and potential patients.

The following table reflects our capital expenditures for the three and nine months ended September 30, 2016 and 2015 (dollars in millions):

	Three Months Ended		Nine Months Ended	
	September 30,		September 30,	
	2016	2015	2016	2015
Capital and routine projects	\$ 71.3	\$ 35.0	\$ 158.1	\$ 113.5
Information systems	32.1	24.2	68.2	39.9
	\$ 103.4	\$ 59.2	\$ 226.3	\$ 153.4
Depreciation expense	\$ 85.7	\$ 69.5	\$ 255.5	\$ 205.2
Ratio of capital expenditures to depreciation expense	120.7 %	85.2 %	88.6 %	74.8 %

We have a formal and intensive review procedure for the authorization of capital expenditures that exceed an established threshold. One of the most important financial measures of acceptability for a discretionary capital project is whether its projected discounted cash flow return on investment exceeds our projected cost of capital for that project. We expect to continue to invest in information systems, modern technologies, emergency room and operating room expansions, the construction of medical office buildings for physician expansion and the reconfiguration of the flow of patient care. Additionally, we may from time to time replace existing hospital buildings with new buildings as we evaluate ongoing repair and maintenance costs and other factors that impact the future operations of the existing buildings.

We expect the total level of spending for capital expenditures to be greater in 2016 as compared to 2015 as a result of our various capital commitments in connection with several of our facilities.

Debt

An analysis and roll-forward of our long-term debt, including current maturities, during the first nine months of 2016 is as follows (in millions):

	December 31, 2015	Proceeds from Borrowings	Payments of Borrowings	Debt Issuance Costs, Discount and Premium (a)	Capital Leases Assumed in Connection with Acquisitions	September 30, 2016
Senior Credit Agreement: Term Facility	\$ -	\$ 700.0	\$ (4.4)	\$ -	\$ -	\$ 695.6
Prior Credit Agreement: Prior Term Facility	405.0	-	(405.0)	-	-	-
Incremental Term Loans	222.6	-	(222.6)	-	-	-
Prior Revolving Facility	-	150.0	(150.0)	-	-	-
6.625% Senior Notes	400.0	-	(400.0)	-	-	-
5.5% Senior Notes	1,100.0	-	-	-	-	1,100.0
5.875% Senior Notes	500.0	-	-	-	-	500.0
5.375% Senior Notes	-	500.0	-	-	-	500.0
Unamortized debt issuance costs, discount and premium	(22.2)	-	-	(0.6)	-	(22.8)
Capital leases and financing obligations	63.4	-	(3.8)	-	78.3	137.9
	\$ 2,668.8	\$ 1,350.0	\$ (1,185.8)	\$ (0.6)	\$ 78.3	\$ 2,910.7

(a) Represents new capitalized debt issuance costs of approximately \$12.0 million, write-offs of previously capitalized debt issuance costs and debt discount of approximately \$8.1 million and amortization of debt issuance costs, discount and premium of \$3.3 million.

Table of Contents

We use leverage, or our total debt to total capitalization ratio, to make financing decisions. The following table illustrates our financial statement leverage and the classification of our debt, all of which was senior, as either fixed rate or variable rate at September 30, 2016 and December 31, 2015 (dollars in millions):

	September 30, 2016	December 31, 2015	Increase (Decrease)
Current portion of long-term debt	\$ 21.5	\$ 25.0	\$ (3.5)
Long-term debt, net	2,889.2	2,643.8	245.4
Unamortized debt issuance costs, discount and premium	22.8	22.2	0.6
Total debt, excluding unamortized debt issuance costs, discount and premium	2,933.5	2,691.0	242.5
Total LifePoint Health, Inc. stockholders' equity	2,204.9	2,263.9	(59.0)
Total capitalization	\$ 5,138.4	\$ 4,954.9	\$ 183.5
Total debt to total capitalization	57.1 %	54.3 %	280 bps
Percentage of total debt:			
Fixed rate debt	76.3 %	76.7 %	
Variable rate debt	23.7	23.3	
	100.0 %	100.0 %	

Capital Resources

Senior Credit Agreement

Terms

On June 10, 2016, we replaced the Prior Credit Agreement with the Senior Credit Agreement maturing on June 10, 2021. The Senior Credit Agreement provides for the \$700.0 million Term Facility and a \$600.0 million Revolving Facility. The proceeds from the Term Facility were used to repay the outstanding Prior Term Facility and Incremental Term Loans under our Prior Credit Agreement and to pay related fees and expenses, and thereafter, for general corporate purposes. The Term Facility requires scheduled quarterly repayments in an amount equal to 2.5% per annum for each of the first, second and third years and 5.0% per annum for the fourth year and first three quarters of the fifth year with the balance due at maturity. Additionally, the Term Facility is subject to mandatory repayments based on excess cash flow, as well as upon the occurrence of certain other events, as specifically described in the

Senior Credit Agreement. The Senior Credit Agreement is guaranteed, on a senior basis, by our subsidiaries that guaranteed the Prior Credit Agreement, subject to certain exceptions. The Senior Credit Agreement is secured by collateral consisting of a perfected first priority lien on, and pledge of, all of the capital stock and intercompany notes issued by our subsidiaries and owned by us and each guarantor, subject to certain exceptions.

Letters of Credit and Availability

The Revolving Facility may be utilized for letters of credit and swingline loans up to a maximum of \$100.0 million and \$50.0 million, respectively. Issued letters of credit and outstanding swingline loans reduce the amounts available under the Revolving Facility. As of September 30, 2016, we had \$22.0 million in letters of credit outstanding that were primarily related to the self-insured retention level of its general and professional liability insurance and workers' compensation programs as security for the payment of claims. Under the terms of the Senior Credit Agreement, amounts available for borrowing under the Revolving Facility were \$578.0 million as of September 30, 2016.

The Senior Credit Agreement may, subject to certain conditions and to receipt of commitments from new or existing lenders, be increased up to the sum of (i) \$800.0 million and (ii) an amount such that, after giving pro forma effect to such increase and to the use of proceeds therefrom, our secured leverage ratio does not exceed 3.50:1.00; provided that no lender is obligated to participate in any such increase.

Table of Contents

Interest Rates

Interest on the outstanding borrowings under the Senior Credit Agreement is payable at our option at either an adjusted London Interbank Offer Rate (“LIBOR”) or an adjusted base rate plus an applicable margin. The applicable margin under the Senior Credit Agreement ranges from 1.50% to 2.00% for LIBOR loans and from 0.50% to 1.00% for adjusted base rate loans based on our total leverage ratio, calculated in accordance with the Senior Credit Agreement. As of September 30, 2016, the applicable annual interest rate under the Term Facility was 2.27%, which was based on the 30-day adjusted LIBOR of 0.52% plus the applicable margin.

Covenants

The Senior Credit Agreement requires us to satisfy a maximum total leverage ratio not to exceed 5.00:1.00 through June 30, 2018 with a step-down to 4.50:1.00 through the remaining term and as calculated on a trailing four quarter basis. We were in compliance with this covenant as of September 30, 2016.

In addition, the Senior Credit Agreement contains certain customary affirmative and negative covenants, which place limitations on the ability of us and our subsidiaries to, among other things, incur debt, create other liens on our assets, make investments, sell assets, pay dividends or distributions to stockholders, undertake transactions with affiliates and enter into merger transactions or consolidate with other companies. The Senior Credit Agreement also contains various customary representations and warranties, financial and collateral reporting requirements and other affirmative covenants.

5.5% Senior Notes

On December 6, 2013 and again on May 12, 2014, we issued in two separate private placements \$700.0 million aggregate principal amount and \$400.0 million aggregate principal amount, respectively, of 5.5% unsecured senior notes (the “5.5% Senior Notes”). Collectively, the 5.5% Senior Notes mature on December 1, 2021 and bear interest at the rate of 5.5% per year, payable semi-annually on June 1 and December 1. The 5.5% Senior Notes are jointly and severally guaranteed on an unsecured senior basis by certain of our existing and future domestic subsidiaries.

We may redeem up to 35% of the aggregate principal amount of the 5.5% Senior Notes, at any time before December 1, 2016, with the net cash proceeds of certain equity offerings at a redemption price equal to 105.500% of the principal amount to be redeemed, plus accrued and unpaid interest, provided that at least 65% of the aggregate principal amount of the 5.5% Senior Notes remain outstanding immediately after the occurrence of such redemption and such redemption occurs within 180 days of the date of the closing of any such qualified equity offering.

We may redeem the 5.5% Senior Notes, in whole or in part, at any time prior to December 1, 2016 at a price equal to 100% of the principal amount of the notes redeemed plus an applicable make-whole premium, plus accrued and unpaid interest, if any, to the date of redemption. We may redeem the 5.5% Senior Notes, in whole or in part, at any time on or after December 1, 2016, for a redemption price equal to a percentage of the principal amount of the notes redeemed (plus accrued and unpaid interest, if any, to the date of redemption) based on the following redemption schedule:

December 1, 2016 to November 30, 2017 104.125 %

Edgar Filing: LIFEPOINT HEALTH, INC. - Form 10-Q

December 1, 2017 to November 30, 2018	102.750 %
December 1, 2018 to November 30, 2019	101.375 %
December 1, 2019 and thereafter	100.000 %

If we experience a change in control under certain circumstances, we must offer to purchase the notes at a purchase price equal to 101% of the principal amount, plus accrued and unpaid interest to the date of purchase.

The 5.5% Senior Notes contain customary affirmative and negative covenants, which among other things, limit our ability to incur additional debt, create liens, pay dividends, effect transactions with our affiliates, sell assets, pay subordinated debt, merge, consolidate, enter into acquisitions and effect sale leaseback transactions.

Table of Contents

5.875% Senior Notes

On December 4, 2015, we issued in a public offering \$500.0 million aggregate principal amount of 5.875% unsecured senior notes due December 1, 2023. The 5.875% Senior Notes bear interest at the rate of 5.875% per year, payable semi-annually on June 1 and December 1. The 5.875% Senior Notes are jointly and severally guaranteed on an unsecured senior basis by certain of our existing and future domestic subsidiaries.

We may redeem up to 35% of the aggregate principal amount of the 5.875% Senior Notes, at any time before December 1, 2018, with the net cash proceeds of certain equity offerings at a redemption price equal to 105.875% of the principal amount to be redeemed, plus accrued and unpaid interest, provided that at least 65% of the aggregate principal amount of the 5.875% Senior Notes remain outstanding immediately after the occurrence of such redemption and such redemption occurs within 180 days of the date of the closing of any such qualified equity offering.

We may redeem the 5.875% Senior Notes, in whole or in part, at any time prior to December 1, 2018 at a price equal to 100% of the principal amount of the notes redeemed plus an applicable make-whole premium, plus accrued and unpaid interest, if any, to the date of redemption. We may redeem the 5.875% Senior Notes, in whole or in part, at any time on or after December 1, 2018, plus accrued and unpaid interest, if any, to the date of redemption plus a redemption price equal to a percentage of the principal amount of the notes redeemed based on the following redemption schedule:

December 1, 2018 to November 30, 2019	104.406 %
December 1, 2019 to November 30, 2020	102.938 %
December 1, 2020 to November 30, 2021	101.469 %
December 1, 2021 and thereafter	100.000 %

If we experience a change in control under certain circumstances, we must offer to purchase the notes at a purchase price equal to 101% of the principal amount, plus accrued and unpaid interest to the date of purchase.

The 5.875% Senior Notes contain customary affirmative and negative covenants, which among other things, limit our ability to incur additional debt, create liens, pay dividends, effect transactions with our affiliates, sell assets, pay subordinated debt, merge, consolidate, enter into acquisitions and effect sale leaseback transactions.

5.375% Senior Notes

On May 26, 2016, we issued in a private placement \$500.0 million aggregate principal amount of 5.375% unsecured senior notes due May 1, 2024. The proceeds from this issuance were used to redeem all \$400.0 million aggregate principal amount of our outstanding 6.625% Senior Notes at a redemption price of 103.313% of principal amount plus accrued and unpaid interest to the redemption date of June 13, 2016. The remaining proceeds were used for general corporate purposes. The 5.375% Senior Notes bear interest at the rate of 5.375% per year, payable semi-annually on May 1 and November 1. The 5.375% Senior Notes are jointly and severally guaranteed on an unsecured senior basis by certain of our existing and future domestic subsidiaries.

We may redeem up to 35% of the aggregate principal amount of the 5.375% Senior Notes, at any time before May 1, 2019, with the net cash proceeds of certain equity offerings at a redemption price equal to 105.375% of the principal amount to be redeemed, plus accrued and unpaid interest, provided that at least 65% of the aggregate principal amount

of the 5.375% Senior Notes remain outstanding immediately after the occurrence of such redemption and such redemption occurs within 180 days of the date of the closing of any such qualified equity offering.

We may redeem the 5.375% Senior Notes, in whole or in part, at any time prior to May 1, 2019 at a price equal to 100% of the principal amount of the notes redeemed plus an applicable make-whole premium, plus accrued and unpaid interest, if any, to the date of redemption. We may redeem the 5.375% Senior Notes, in whole or in part, at any time on or after May 1, 2019 at the redemption prices (expressed as percentages of principal amount) listed below, plus accrued and unpaid interest, if any, to the date of redemption:

May 1, 2019 to April 30, 2020	104.031 %
May 1, 2020 to April 30, 2021	102.688 %
May 1, 2021 to April 30, 2022	101.344 %
May 1, 2022 and thereafter	100.000 %

Table of Contents

If we experience a change in control under certain circumstances, we must offer to purchase the notes at a purchase price equal to 101% of the principal amount, plus accrued and unpaid interest to the date of purchase.

The 5.375% Senior Notes contain customary restrictive covenants, which among other things, limit the ability of us and our subsidiaries to incur or guarantee additional indebtedness; pay dividends on, or redeem or repurchase, our capital stock; make investments; incur obligations that restrict our subsidiaries from making dividend or other payment to us; sell or encumber our assets; engage in transactions with affiliates; enter into sale/leaseback transactions; and merge, consolidate, or transfer all or substantially all of our assets.

In connection with the issuance of the 5.375% Senior Notes, we agreed to use commercially reasonable efforts to register with the SEC exchange notes having substantially identical terms as the 5.375% Senior Notes and complete an exchange offer no later than 395 calendar days after the issuance date of the 5.375% Senior Notes. Under certain circumstances, we may be required to file a shelf registration statement with respect to the 5.375% Senior Notes. If we fail to meet these obligations, we have agreed to pay additional interest to the holders of the affected 5.375% Senior Notes under certain circumstances.

Liquidity and Capital Resources Outlook

We expect the total level of spending for capital expenditures to be greater in 2016 as compared to 2015 as a result of our various capital commitments in connection with several of our facilities.

At September 30, 2016, we had uncompleted projects with an estimated additional cost to complete and equip of approximately \$611.3 million. We anticipate funding these expenditures through cash provided by operating activities, available cash and borrowings available under the Senior Credit Agreement.

Our business strategy contemplates the selective acquisition of additional hospitals and other healthcare service providers, and we regularly review potential acquisitions. These acquisitions may, however, require additional financing. We regularly evaluate opportunities to sell additional equity or debt securities, obtain credit agreements from lenders or restructure our long-term debt or equity for strategic reasons or to further strengthen our financial position. The sale of additional equity or convertible debt securities could result in additional dilution to our stockholders.

Our primary sources of liquidity are cash flows provided by our operations and our debt borrowings. We believe that our internally generated cash flows and amounts available for borrowing under our current Senior Credit Agreement will be adequate to service existing debt, finance internal growth and fund capital expenditures and small to mid-size hospital acquisitions over the next twelve months and into the foreseeable future prior to maturity dates of our outstanding debt. Certain larger hospital acquisitions may, however, require additional financing.

Contractual Obligations

We have various contractual obligations, which are recorded as liabilities in our accompanying unaudited condensed consolidated financial statements. Other items, such as certain purchase commitments and other executory contracts, are not recognized as liabilities in our accompanying unaudited condensed consolidated financial statements but are required to be disclosed. For example, we are required to make certain minimum lease payments for the use of property under certain of our operating lease agreements. During the three months ended September 30, 2016, there were no material changes in our contractual obligations as presented in our 2015 Annual Report on Form 10-K and our quarterly report on Form 10-Q for the three months ended June 30, 2016.

Off-Balance Sheet Arrangements

As of September 30, 2016, we had \$22.0 million in letters of credit outstanding that were primarily related to the self-insured retention level of our general and professional liability insurance and workers' compensation programs as security for the payment of claims.

Table of Contents

Adoption of Recently Issued Accounting Standards

ASU 2015-16, “Business Combinations: Simplifying the Accounting for Measurement-Period Adjustments”

In September 2015, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2015-16, “Business Combinations: Simplifying the Accounting for Measurement-Period Adjustments” (“ASU 2015-16”). ASU 2015-16 eliminates the requirement for an acquirer to retrospectively adjust its financial statements for changes to provisional amounts that are identified during the measurement-period following the consummation of a business combination. Instead, ASU 2015-16 requires these types of adjustments to be made during the reporting period in which they are identified and would require additional disclosure or separate presentation of the portion of the adjustment that would have been recorded in the previously reported periods as if the adjustment to the provisional amounts had been recognized as of the acquisition date. We adopted ASU 2015-16 during the first quarter of 2016, which had no impact on our financial position, results of operation, cash flows or financial disclosures.

ASU 2015-5, “Intangibles – Goodwill and Other – Internal-Use Software”

In April 2015, the FASB issued ASU 2015-5, “Intangibles - Goodwill and Other - Internal-Use Software” (“ASU 2015-5”). ASU 2015-5 provides guidance to customers about whether a cloud computing arrangement includes a software license. If a cloud computing arrangement includes a software license, ASU 2015-5 specifies that the customer should account for the software license element of the arrangement consistent with the acquisition of other software licenses. ASU 2015-5 further specifies that the customer should account for a cloud computing arrangement as a service contract if the arrangement does not include a software license. We prospectively adopted the provisions of ASU 2015-5 during the first quarter of 2016, which had no material impact on our financial position, results of operation, cash flows or financial disclosures.

ASU 2015-2, “Consolidation”

In February 2015, the FASB issued ASU 2015-2 “Consolidation” (“ASU 2015-2”). ASU 2015-2 includes amendments that are intended to improve targeted areas of consolidation for legal entities including reducing the number of consolidation models from four to two and simplifying the FASB Accounting Standards Codification. We adopted ASU 2015-2 during the first quarter of, 2016, which had no impact on our financial position, results of operation, cash flows or financial disclosures.

Accounting Standards Not Yet Adopted

ASU 2016-9, “Compensation – Stock Compensation: Improvements to Employee Share-Based Payment Accounting”

In March 2016, the FASB issued ASU 2016-9 “Compensation – Stock Compensation: Improvements to Employee Share-Based Payment Accounting” (“ASU 2016-9”). ASU 2016-9 changes certain aspects of accounting for share-based payment awards to employees, including the accounting for income taxes, application of estimated rates of forfeiture and statutory tax withholding requirements. ASU 2016-9 is effective for annual reporting periods beginning after December 15, 2016, including interim periods within those years. Early adoption is permitted. We are currently evaluating the impact that the adoption of this standard will have on our financial position, results of operations and cash flows.

ASU 2016-2, “Leases”

In February 2016, the FASB issued ASU 2016-2 “Leases” (“ASU 2016-2”). ASU 2016-2 requires the rights and obligations arising from lease contracts, including existing and new arrangements, to be recognized as assets and liabilities on the balance sheet. ASU 2016-2 is effective for annual reporting periods beginning after December 15, 2018, including interim periods within those years. Early adoption is permitted. We anticipate that the adoption of ASU 2016-2 will result in an increase in both total assets and total liabilities. We are still evaluating the impact that the adoption of this standard will have on our policies, procedures and control framework.

Table of Contents

ASU 2014-9, “Revenue from Contracts with Customers”

In May 2014, the FASB issued ASU 2014-9, “Revenue from Contracts with Customers” (“ASU 2014-9”). ASU 2014-9 provides for a single comprehensive principles-based standard for the recognition of revenue across all industries through the application of the following five-step process:

Step 1: Identify the contract(s) with a customer.

Step 2: Identify the performance obligations in the contract.

Step 3: Determine the transaction price.

Step 4: Allocate the transaction price to the performance obligations in the contract.

Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation.

Among other provisions and in addition to expanded disclosure about the nature, amount, timing and uncertainty of revenue as well as certain additional quantitative and qualitative disclosures, ASU 2014-9 changes the healthcare industry specific presentation guidance under ASU 2011-7, “Presentation and Disclosure of Patient Service Revenue, Provision for Bad Debts, and the Allowance for Doubtful Accounts for Certain Health Care Entities.” The provisions of ASU 2014-9 are effective for annual periods beginning after December 15, 2017, including interim periods within those years. Early adoption is permitted starting with annual periods beginning after December 31, 2016. We are still evaluating the impact that the adoption of this standard will have on our revenue recognition policies, procedures, financial position, results of operations, cash flows, financial disclosures and control framework.

Critical Accounting Estimates

The preparation of financial statements in accordance with U.S. generally accepted accounting principles requires us to make estimates and assumptions that affect reported amounts and related disclosures. We consider an accounting estimate to be critical if:

- it requires assumptions to be made that were uncertain at the time the estimate was made; and
- changes in the estimate or different estimates that could have been made could have a material impact on our consolidated results of operations or financial condition.

Our critical accounting estimates include the following areas:

- Revenue recognition and accounts receivable;
- Goodwill impairment analysis;
- Reserves for self-insurance claims;
- Accounting for stock-based compensation; and
- Accounting for income taxes.

Contingencies

Please refer to Note 10 to our accompanying unaudited condensed consolidated financial statements included elsewhere in this report for a discussion of our material financial contingencies, including:

- Legal proceedings and general liability claims;
- Physician commitments;
- Capital expenditure commitments;
- Acquisitions; and
- Marquette replacement facility.

Table of Contents

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

Interest Rates

The following discussion relates to our exposure to market risk based on changes in interest rates:

Outstanding Debt

As of September 30, 2016, we had outstanding debt, excluding unamortized debt issuance costs and premium, of \$2,933.5 million, 23.7%, or \$695.6 million, of which was subject to variable rates of interest. If the interest rate on our variable rate long-term debt outstanding as of September 30, 2016 was 100 basis points higher during the nine months ended September 30, 2016, our net income would have decreased by approximately \$3.3 million, or \$0.07 per diluted share.

Cash Balances

Certain of our outstanding cash balances are invested overnight with high credit quality financial institutions. We do not hold direct investments in auction rate securities, collateralized debt obligations, structured investment vehicles or mortgage-backed securities. We did not have significant exposure to changing interest rates on invested cash at September 30, 2016. As a result, the interest rate market risk implicit in these investments at September 30, 2016, if any, was low.

Item 4. Controls and Procedures.

We carried out an evaluation, under the supervision and with the participation of management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this report pursuant to Rule 13a-15 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective in ensuring that information required to be disclosed by us (including our consolidated subsidiaries) in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported on a timely basis.

There has been no change in our internal control over financial reporting during the three months ended September 30, 2016 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

Table of Contents

PART II – OTHER INFORMATION

Item 1. Legal Proceedings.

Healthcare facilities are, from time to time, subject to claims and suits arising in the ordinary course of business, including claims for damages for personal injuries, medical malpractice, breach of contracts, wrongful restriction of or interference with physicians' staff privileges and employment related claims. In certain of these actions, plaintiffs request payment for damages, including punitive damages that may not be covered by insurance.

In addition, healthcare facilities are subject to the regulation and oversight of various state and federal governmental agencies. Further, under the federal False Claims Act, private parties have the right to bring qui tam, or "whistleblower," suits against healthcare facilities that submit false claims for payments to, or improperly retain overpayments from, governmental payors. Some states have adopted similar state whistleblower and false claims provisions. These qui tam or "whistleblower" actions initiated under the civil False Claims Act may be pending but placed under seal by the court to comply with the False Claims Act's requirements for filing such suits. As a result, they could be proceeding without our knowledge. In addition, on June 30, 2016, in accordance with the requirements of the Federal Civil Penalties Inflation Adjustment Act Improvements Act of 2015, the DOJ published an interim final rule that, effective as of August 1, 2016, increases the civil monetary penalties that may be imposed for violations of the False Claims Act from a minimum of \$5,500 and a maximum of \$11,000 to a minimum of \$10,781 and a maximum of \$21,563 for each false and fraudulent claim. The interim final rule also establishes a mechanism for increasing the amounts of those civil monetary penalties for inflation on an annual basis beginning in 2017 and continuing each year thereafter. These civil monetary penalties are in addition violators' liability for three times the amount of damages which the government sustains as a result of the false or fraudulent claim.

Although the healthcare industry has seen numerous ongoing investigations related to compliance and billing practices, hospitals, in particular, continue to be a primary enforcement target for the OIG, the DOJ and other governmental fraud and abuse programs. Certain of our individual facilities have received, and from time to time, other facilities may receive, inquiries or subpoenas from fiscal intermediaries, and federal and state agencies. Any proceedings against us may involve potentially substantial amounts as well as the possibility of civil, criminal, or administrative fines, penalties, or other sanctions, which could be material. Settlements of suits involving Medicare and Medicaid issues routinely require both monetary payments as well as corporate integrity agreements. Depending on whether the underlying conduct in these or future inquiries or investigations could be considered systemic, their resolution could have a material adverse effect on our financial position, results of operations and liquidity.

The Affordable Care Act imposed an affirmative obligation on healthcare providers to report and refund any overpayments received. "Overpayments" in this context include any amount received from a government program by a provider to which it is not entitled, regardless of the cause. Such overpayments are deemed to be fraudulent and become violations of the False Claims Act if not reported and refunded within the later of 60 days of identification or the date any corresponding cost report is due (if applicable). Hospitals can meet the obligation to report and refund in three ways: (1) refunding overpayments directly to the program; (2) self-disclosing the overpayment to the OIG via its voluntary self-disclosure protocol (with respect to False Claims Act and other violations not related to the federal

physician self-referral law (Stark law)); and (3) self-disclosing to CMS via the self-referral disclosure protocol (with respect to overpayments caused by potential violations of the Stark law only) for which CMS has the authority to reduce the amounts otherwise owed.

We do not control and cannot predict with certainty the progress or final outcome of discussions with government agencies, investigations and legal proceedings against us. Therefore, the final amounts paid to resolve such matters, claims and obligations could be material and could materially differ from amounts currently recorded, if any. Any such changes in our estimates or any adverse judgments could materially adversely impact our future results of operations and cash flows.

In connection with our acquisitions of Marquette General Hospital (“Marquette General”) and Conemaugh Health System (“Conemaugh”), the two sellers self-disclosed various potentially non-compliant physician arrangements under the CMS voluntary self-disclosure protocol. These self-disclosures are pending with CMS. With respect to Marquette General, to the extent that the seller’s satisfaction of its retained liabilities, including those under its CMS voluntary self-disclosure, causes its net proceeds from the acquisition to be less than \$15.0 million, we have agreed to pay additional purchase consideration to the seller. With respect to Conemaugh, to the extent that the potential settlement exceeds the seller’s indemnification threshold in accordance with the asset purchase agreement, we will likely be responsible for funding any deficit. We believe we have made reasonable estimates of our potential exposure for these two matters, and at September 30, 2016, we have recorded a reserve for Marquette General of \$18.0 million.

Table of Contents

On September 16, 2013, we and two of our affiliated hospitals, Vaughan Regional Medical Center, located in Selma, Alabama, and Raleigh General Hospital, located in Raleigh, West Virginia, made a voluntary self-disclosure to the Civil Division of the Department of Justice. The voluntary self-disclosure related to concerns regarding the clinical appropriateness of certain interventional cardiology procedures conducted by one physician in each of these hospitals' cardiac catheterization laboratories. On September 24, 2013, the U.S. Attorney's Office in the Southern District of West Virginia served a subpoena on Raleigh General Hospital. Raleigh General Hospital produced responsive documents to the subpoena, including patient files. The government investigations are ongoing and we continue to cooperate with the government in addressing these matters. Following reviews by independent interventional cardiologists, we notified patients of these two physicians who may have received an unnecessary procedure of such fact.

We and/or Vaughan Regional Medical Center and several of our subsidiaries, as well as Dr. Seydi V. Aksut and certain parties unaffiliated with us, are named defendants in 26 individual lawsuits filed since December 2014, and two putative class action lawsuits, all filed in the Circuit Court of Dallas County, Alabama. These lawsuits allege that patients at Vaughan Regional Medical Center underwent improper interventional cardiology procedures. One of the putative class action lawsuits, filed on November 21, 2014, seeks certification of a class consisting of all Alabama citizens who underwent an invasive cardiology procedure at any Company-owned Alabama hospital and who received notice regarding the medical necessity of that procedure. The other putative class action lawsuit, filed on February 6, 2015 also in the Circuit Court for Dallas County, Alabama, seeks certification of a class of individuals that underwent an interventional cardiology procedure that was not medically necessary and performed by Dr. Aksut. This action asserts, among other claims, claims under the Racketeer Influenced and Corrupt Organizations Act ("RICO"), which, if successful, would result in the awarding of treble damages for any injury resulting from the RICO violation and attorneys' fees. In March 2015, we removed this action to the U.S. District Court in Mobile, Alabama and filed a motion to dismiss and for summary judgment, as well as a stay of discovery pending resolution of these motions. On April 17, 2015 the court entered an order granting the requested stay of discovery. On November 17, 2015, the United States Magistrate Judge for the Southern District of Alabama filed a Report and Recommendation that the RICO claim be dismissed with prejudice, and that the court not exercise jurisdiction over the remaining state law claims, resulting in those claims being dismissed without prejudice. By Order dated March 28, 2016, the United States District Court Judge adopted in full the Report and Recommendation of the Magistrate, dismissing with prejudice the RICO claim and refusing to exercise jurisdiction over the remaining state law claims. In a filing made April 7, 2016 the plaintiffs appealed the District Court's Order to the United States Court of Appeals for the Eleventh Circuit.

Additionally, we, and two of our subsidiaries, including Raleigh General Hospital, as well as Dr. Kenneth Glaser, have been named in 82 individual lawsuits filed in the circuit court of Raleigh County, West Virginia. These lawsuits allege that patients at Raleigh General Hospital underwent unnecessary interventional cardiology procedures. Through September 30, 2016, one additional patient has notified Raleigh General Hospital that he intends to file a lawsuit against the hospital.

The lawsuits identified above variously seek compensatory and punitive damages, costs, attorneys' fees and other available damages. Additional claims, including claims involving patients to whom we did not send notice, have been threatened and may be asserted against us or the hospital. Any present or future claims that are ultimately successful could result in us and/or the hospitals being found liable and the government investigations may also result in damages, fines and penalties. Such liability, damages and penalties could be material.

We accrue an estimate for a contingent liability when losses are both probable and reasonably estimable. We review our accruals each quarter and adjust them to reflect the impact of developments, advice of legal counsel and other information pertaining to a particular matter. During the nine months ended September 30, 2016, we recorded an

accrual for loss contingencies for cardiology-related lawsuits, which resulted in a net expense of \$24.7 million, \$15.5 million net of income taxes, or \$0.35 loss per diluted share.

Item 1A. Risk Factors.

There have been no material changes in our risk factors from those disclosed in the 2015 Annual Report on Form 10-K.

62

Table of Contents

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

Our Board of Directors has authorized the repurchase of outstanding shares of our common stock either in the open market or through privately negotiated transactions, subject to market conditions, regulatory constraints and other customary factors in accordance with a repurchase plan adopted in 2014, as subsequently amended and extended in October 2015 (the “2014 Repurchase Plan”), a repurchase plan adopted on June 3, 2015 (the “2015 Repurchase Plan”) and a repurchase plan adopted on September 14, 2016 (the “2016 Repurchase Plan”). The 2014 Repurchase Plan and 2015 Repurchase Plan each provided for the repurchase of up to \$150.0 million in shares of our common stock, and we have repurchased all shares authorized for repurchase under these plans. The 2016 Repurchase Plan provides for the repurchase of up to \$200.0 million in shares of our common stock through March 14, 2018. As of September 30, 2016, we had remaining authority to repurchase \$174.0 million in shares in accordance with the 2016 Repurchase Plan. We are not obligated to repurchase any specific number of shares under the 2016 Repurchase Plan. We have designated the shares repurchased in accordance with our repurchase plans as treasury stock.

We repurchased approximately 2.5 million and 1.2 million shares for an aggregate purchase price, including commissions, of \$151.0 million and \$92.5 million at an average purchase price of \$60.13 and \$75.84 per share during the nine months ended September 30, 2016 and 2015, respectively.

Additionally, we redeem shares from employees for minimum statutory tax withholding purposes upon vesting of certain stock awards granted pursuant to our various stockholder approved stock-based compensation plans. We redeemed approximately 0.2 million shares vested under these plans during each of the nine months ended September 30, 2016 and 2015 for aggregate purchase prices of approximately \$8.0 million and \$9.5 million, respectively. We have designated these shares as treasury stock.

The following table summarizes our share repurchase activity by month for the three months ended September 30, 2016:

	Total Number of Shares Purchased	Weighted Average Price Paid per Share	Total Number of Shares Purchased as Part of a Publicly Announced Programs	Approximate Dollar Value of Shares that May Yet Be Purchased Under the Programs (In millions)
July 1, 2016 to July 31, 2016	-	\$ -	-	\$ 75.0

Edgar Filing: LIFEPOINT HEALTH, INC. - Form 10-Q

August 1, 2016 to August 31, 2016	1,305,414	\$ 57.45	1,305,414	\$ -
September 1, 2016 to September 30, 2016 (a)	455,698	\$ 57.99	447,976	\$ 174.0
Total	1,761,112	\$ 57.59	1,753,390	\$ 174.0

(a) Includes shares redeemed for tax withholding purposes upon vesting of certain previously granted stock awards under our various stockholder-approved stock-based compensation plans.

Table of Contents

Item 6. Exhibits

Exhibit Number	Description of Exhibits
3.1	- by Amended and Restated Certificate of Incorporation of LifePoint Health, Inc., as amended (incorporated by reference from exhibits to the LifePoint Health, Inc. Quarterly Report on Form 10-Q for the quarter ended June 30, 2015, File No. 000-51251).
3.2	- to Sixth Amended and Restated By-Laws of LifePoint Health, Inc. (incorporated by reference from exhibits to the LifePoint Health, Inc. Current Report on Form 8-K filed May 11, 2015, File No. 000-51251).
31.1	- Certification of the Chief Executive Officer of LifePoint Health, Inc. pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2	- Certification of the Chief Financial Officer of LifePoint Health, Inc. pursuant to Section 302 of the Sarbanes Oxley Act of 2002.
32.1	- Certification of the Chief Executive Officer of LifePoint Health, Inc. pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2	- Certification of the Chief Financial Officer of LifePoint Health, Inc. pursuant to Section 906 of the Sarbanes Oxley Act of 2002.
101.INS	- XBRL Instance Document*
101.SCH	- XBRL Taxonomy Extension Schema Document*
101.CAL	- XBRL Taxonomy Calculation Linkbase Document*
101.DEF	- XBRL Taxonomy Definition Linkbase Document*
101.LAB	- XBRL Taxonomy Label Linkbase Document*
101.PRE	- XBRL Taxonomy Presentation Linkbase Document*

* — Furnished electronically herewith

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

LifePoint Health, Inc.

By:/s/ Michael S. Coggin

Michael S. Coggin

Executive Vice President and

Chief Financial Officer

(Principal Accounting Officer)

Date: October 28, 2016

Table of Contents

Exhibit Number	Description of Exhibits
3.1	- by Amended and Restated Certificate of Incorporation of LifePoint Health, Inc., as amended (incorporated by reference from exhibits to the LifePoint Health, Inc. Quarterly Report on Form 10-Q for the quarter ended June 30, 2015, File No. 000-51251).
3.2	- to Sixth Amended and Restated By-Laws of LifePoint Health, Inc. (incorporated by reference from exhibits to the LifePoint Health, Inc. Current Report on Form 8-K filed May 11, 2015, File No. 000-51251).
31.1	- Certification of the Chief Executive Officer of LifePoint Health, Inc. pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2	- Certification of the Chief Financial Officer of LifePoint Health, Inc. pursuant to Section 302 of the Sarbanes Oxley Act of 2002.
32.1	- Certification of the Chief Executive Officer of LifePoint Health, Inc. pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2	- Certification of the Chief Financial Officer of LifePoint Health, Inc. pursuant to Section 906 of the Sarbanes Oxley Act of 2002.
101.INS	- XBRL Instance Document*
101.SCH	- XBRL Taxonomy Extension Schema Document*
101.CAL	- XBRL Taxonomy Calculation Linkbase Document*
101.DEF	- XBRL Taxonomy Definition Linkbase Document*
101.LAB	- XBRL Taxonomy Label Linkbase Document*
101.PRE	- XBRL Taxonomy Presentation Linkbase Document*

* — Furnished electronically herewith

